

Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

Date: 01-04-2025

To,
The Managing Director,
Uttar Pradesh Medical Suplies Corporation Limited,
Lucknow

Sub: Regarding clarification/representation of Provisional List of bidders/items of tenderno. UPMSCL/Drugs-223/25, Date: 27.03.2025.

Respected Sir,

In reference to the above cited subject we are submitted our representation point wise.

Firm not Eligibility Remarks:1. Turnover figure for the F.Y. 23- 24 not matched with FS vs ATC 2. Hence, turnover criteria not fulfilled.

Representation: We are resubmitting Revised ATC with Mentioned UDIN as desired. Page No- 28

Firm not Eligibility Remarks: 3. In Format I, name of authorized person for submitting bid and signing contract is not mentioned.

Representation: We are submitting the format 1 with name, designation & contact no of the authorised person.Page No- 1

Firm not Eligibility Remarks: .60 days/ Annual production capacity certificate issued by Licensing Authority is not submitted.

Representation:We are attaching 60 days Production capacity certificate by Licensing Authority Himachal Pradesh. **Page No- 27**

Firm not Eligibility Remarks:.5. In Format X, cancelled cheque is not attached.

Representation: We are attaching the cancelled cheque. Page No- 43

Firm not Eligibility Remarks: 6. Format XI is not executed by the authorized person.

Representation: We are resubmitting the format XI as desired. Page No-44-45

Firm not Eligibility Remarks: 7. Statuary documents are not notarized.

Representation: We are resubmitting notarized Statuary documents as you desired.

Item Not eligibility remark: Febuxostat 40 mg tab 1*10strip,D260003(Pharmacopoeial reference is not mentioned on product permission and market standing certificate).

Sed Signa



Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

Representation:For Item Code no. D260003- Since the formulation required by you is not officially in any Pharmacopeia; accordingly the State drug department has issued us product permissions as per in house specification. **page no. 14A**

Item Not eligibility remark: Methylprednisolone Injection 40 mg/ml (1ml) 1 ml vialD160016 (1.Product permission is as per BP. 3.In Format V, shelf life is not as per tender requirement.)

Representation:For Item Code no. D160016- We manufacture the quoted product in accordance with the Indian Pharmacopoeia (IP) standards, as per the Drug & Cosmetic Rules, Part XII (attached), in compliance with the law of the land. Furthermore, we ensure that the product is supplied in full compliance with these standards, as per the letter dated 09.01.2023 from our licensing authority.

Item Not eligibility remark: Atorvastatin calcium tablet IP 40 mg 1*10strips, D100046 (Pharmacopoeial reference is not mentioned on market standing certificate.)

Representation: We are manufacture the quoted product in accordance with the Indian Pharmacopoeia (IP) standards as per the Drug & Cosmetic Rules, Part XII (attached) as per law of the land & we will ensure that the product is supplied in full compliance with these standards.

Item Not eligibility remark: Pantaprazole 40 mg (tab) 1*10strip, D020010 (1. Product permission is for enteric coated tablet. 2. Pharmacopoeial reference is not mentioned on Market Standing Certificate and Market standing certificate is for film coated tablet.)

Representation:The approval is as per I.P. Copy of I.P is attached herewith for your reference. 2-We are manufacture the quoted product in accordance with the Indian Pharmacopoeia (IP) standards as per the Drug & Cosmetic Rules, Part XII (attached) as per law of the land & we will ensure that the product is supplied in full compliance with these standards.**Page No-16-17**

Item Not eligibility remark: Thiamine injection 100 mg/ml, 2ml Vial, D340033 (Pharmacopoeial reference is not mentioned on Product Permission.)

Representation:We are manufacture the quoted product in accordance with the Indian Pharmacopoeia (IP) standards as per the Drug & Cosmetic Rules, Part XII (attached) as per law of the land & we will ensure that the product is supplied in full compliance with these standards.**Page No-14**

For SYSTOLE REMEDIES PRIVATE LIMITED



🧿 Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

Format-I

INFORMATIONABOUTBIDDER

- 1. Nameofthebiddingcompany/firm&CIN: Systole Remedies Pvt. Ltd.
- 2. Typeofcompany/firm:(Proprietorship/Partnership/Pvt.Ltd./PublicLtd./PSUetc.)
- a.Whetherthefirm/companyfallsinSSI/MSMEcategory:Yes/Neb.lfMSME,StateinwhichitisregisteredasMSME:
- 4. Abriefhistory of Inception and development:
- 5. CorporateaddressofBidder: village ogli,kala amb, tehsil simour -Himachal

XVIII.

- 1. Participatingintenderas: Manufacturer/Importer/Both
- Average annual turnover (Last 3 years) of the firm related to pharmaceuticals: 95.64/- cr.
 (Based on Information submitted in Format -VI)
- 3. ApproximateannualturnoverinGovt.business:
- 4. Approximateannualturnoverofdomestictrade:
- 5. Approximateannualturnoverofexport:
- 6. No.ofownmanufacturingunitsinIndia: no
- 7. No.ofManufacturingfacilitiesabroad:
- 8. HaveOwnR&D/F&D:Yes/No.IfYes,
 - a. Location:
 - b. No. of Scientist engaged:
 - c. Approximateannualspenton R&D
- Name, Designation & contact detail (including mobile/phone no.) of the authorized person for submitting bid and signing contract.RAVNEET SINGH -DIRECTOR -M: 9828506600
- 10. Name&Designationofthepersonauthorizing: HARS, mRAN SINGH
- 11. Name and contact detail of Owner/Managing Director of the company:RAVNEET SINGH
- 12. E-mailaddressofBidderforcorrespondence:systoleremedies1988@gmail.com

(Note: Allthecorrespondences related to this tender shall only be made on this e-mail)



Page46of70

CHKULA (Haryana)

Notary PAN



o Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

Format-II

PARTICULARSOFTENDERFEEDEPOSITED

(Tobesubmittedalongwithtechnical bid)

- i) ReferenceNo.ofBid: UPMSCL/Drugs-223/25 dt. 24.12.24
- ParticularsofTenderfee:- 5900 ii)
- RTGS/e-TransferReference No. : <u>AXSK250280000409</u> a)
- b) Dateonwhichtransfer made: 28.01.2025
- TransferredAmountRs c) 5900 only.
- NameandaddressofBankthroughwhichtransfermade—AXIS BANK d)
- Name and address of the bidder: SYSTOLE REMEDIES PVT. LTD. e)
- PAN No: AAJCS3700R iii) $(Copy of PAN card duly attested by the bidder under his seal and signature\ to be\ submitted.)$
- GSTNo: 02AAJCS3700R2Z6 iv) (CopyofGSTcertificatedulyattestedbythebidderunderhissealandsignaturetobe submitted)

SIGNATUREOFTHEAUTHORIZEDREPRESENTATIVE

NAME RAVNEET SINGH

DESIGNATION: DIRECTOR

NAMEOFTHE FIRM/BIDDER: SYSTOLE REMEDIES PVT. LTD.__

STAMPOFTHEFIRM/BIDDER_

Attested as identified

29 MAR 2025

Notary PANCHICULA (Harvana)

Page 43 of 67



Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

Format-III

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

PARTICULARSOFEMDDEPOSITED

(Tobesubmittedalongwithtechnical bid)

i.	ReferenceNo.of Bid: UPMSCL/Drugs-223/25 dt. 24.12.24
ii.	ParticularsofEMDsubmitted:- 2LAC
iii.	RTGS/e-TransferReference No. UTIBR52025012800350504_
iv.	Dateonwhichtransfer made
V.	TransferredAmountRs2,OO,OOO/-only(Rupees TWO LAKHS only).
vi.	NameandaddressofBankthroughwhichtransfermade: AXIS BANK
vii.	Name and address of the bidder: SYSTOLE REMEDIES PVT. LTD.
v)	PAN No: AAJCS3700R
viii.	(CopyofPANcarddulyattestedbythebidderunderhissealandsignaturetobe submitted.)
X.	GSTNo: 02AAJCS3700R2Z6
k. Submi	(Copy of GST certificate duly attested by the bidder under his seal and signature to be
	ometine Red

SIGNATUREOFTHEAUTHORIZEDREPRESENTATIVE

NAME: RAVNEET SINGH

DESIGNATION DIRECTOR____

NAMEOFTHEFIRM/BIDDER: SYSTOLE REMEDIES PVT. LTD.__

STAMP OF THEFIRM/BIDDER _____

29 MAR 2025

Attested as identified

Notary, PANCHKULA (Haryana)



Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

Format-IV

$Details of Manufacturing Unit where\ quoted drugs are to be manufactured$

SI.	Addressofthe manufacturing unit	License number and validity	Own premises/Lo an license	Validityof GMPand GLP/WHO- GMP	Regulatory approvalsof the Premises with	1	ofTechi sonenga QC	
	OGLI, TEHSIL	MNB/06/434 & MB/06/435 DT.12.11.2026	12.11.2026	certificate 15.05.2026	validity 12.11.2026	4	4	6

SIGNATUREOFTHEAUTHORIZEDREPRESENTATIVE

NAME____

DESIGNATION

NAMEOFTHEFIRM/BIDDER

STAMPOFTHEFIRM/BIDDER_

OF INDIP

Attested as identified

Notary, PANCHKULA (Haryana)

2 9 MAR 2025

Page45of66

No.: HFW-H (Drugs) 288/06 HEALTH & FAMILY WELFARE DEPARTMENT HIMACHAL PRADESH.

Dated-

Baddi - 173205.

G. M. P. CERTIFICATE

This is to certify that M/s Systole Remedies Pvt. Ltd. Village Ogli, tehsil Nahan, Distt. Sirmaur (H.P.) is holding Drugs Manufacturing Licence in form No. 25 & 28 bearing No. MNB/06/434 & MB/06/435 valid up-to 12.11.2026 for manufacture for sale.

- 1. The firm is following GOOD MANUFACTURING PRACTICES as stipulated under the provisions of "REVISED Schedule "M" of Drugs & Cosmetics Rules, 1945 in respect of category of Drugs & Cosmetics Rules, 1945 in respect of category of : Tablets, Capsules, Small Volume Parenterals, Eye/Ear drops, Oral Liquids & External Tablets, Capsules, Oral Suspension & Small Volume parenterals (Beta Lactam) only.
- 2. The Parent firm should however carry out self-inspection from time to time to ensure that the requirements of Good Manufacturing Practices are complied with.
- 3. This certificate is issued on the request of the firm for the limited purpose of submitted the same in connection with participating in the Tenders in Government Hospitals, Defense, Supply to Non- regulated markets & Institutions.
- 4. This certificate is valid for the period of two years from the date of issue.

M/s Systole Remedies Pvt. Ltd. Village Ogli, tehsil Nahan, Distt. Sirmaur (H.P.)

15.05. WW (GARIMA SHARMA) Vistt! Drugs Controller.

Asseum-Libensing Authority

- cHQ. Baddis Dista Solarity

Hollimachat Pradeshan, H.P.

Attested as identified

Notery, FANCHKULA

No.: HFW-H (Drugs) 188/06 HEALTH & FAMILY WELFARE DEPARTMENT HIMACHAL PRADESH.

Dated-

Baddi - 173205,

G. L. P. CERTIFICATE

This is to certify that M/s Systole Remedies Pvt. Ltd. Village Ogli, tehsil Nahan, Distt. Sirmaur (H.P.) is holding Drugs Manufacturing Licence in form No. 25 & 28 bearing No. MNB/06/434 & MB/06/435 valid up-to 12.11.2026 for manufacture for sale.

- 1. The firm is having well equipped Quality Control Laboratory for testing of drugs: Tablets, Capsules, Small Volume Parenterals, Eye/Ear drops, Oral Liquids & External Preparations (General category) and Tablets, Capsules, Oral Suspension & Small Volume parenterals (Beta Lactam) only, dosage form & following Good Laboratory Practices, as stipulated under the provision "Schedule L-1" of Drugs and Cosmetics Rules 1945.
- 2. This certificate is issued on the request of the firm for the submitting the same to Government Hospitals, Corporations, Defense and Supply to Non-regulated markets & Institutions for tender purpose.
- 3. This certificate is valid for the period of two years from the date of issue.

M/s Systole Remedies Pvt. Ltd. Village Ogli, tehsil Nahan, Distt. Sirmaur (H.P.)

(GarGARIMA SHARMA)



Attested to Bo True Copy

Notary, PANCHKULA (Haryana)



Health & Family Welfare Department, Himachal Pradesh DRUGS CONTROL ADMINISTRATION H.P. Office of Assistant Drugs Controller-cum-Drugs Licensing Authority

CMO Office Complex Nahan (H.Q)District Sirmour, 173001 INDIA Phone No. 01702-222543, email:adc3sirmaur@gmail.com

Dated: 31/08/2024

NON CONVICTION CERTIFICATE

Certified that M/s Systole Remedies Pvt Ltd, situated at Vill. Ogli, Kala Amb, Tehsil Nahan, Distt-Sirmour, 173030 H.P, is licensed to manufacture drugs for sale or distribution, under license No. Form 25: MNB/06/434 and Form 28: MB/06/435 granted on 13.11.2006 and Retained upto 12.11.2026. The firm is installed with the facility to manufacture:

Tablets, Capsules, Oral Liquids, External Preparations & SVP (General Category Only)
Tablets, Dry Syrup & SVP (Beta Lactam Category Only)

As per this Office record, it is certified that the said firm has not been convicted under the provision of the Drugs and Cosmetic Act. 1940 and Rules 1945 made there under, in the State of Himachal Pradesh, from the day of grant of licenses.

The certificate is issued to the firm on their request and is meant for the limited purpose i.e. for participating in the Government tenders pertaining to the supplies meant for hospital, defense & other non-regulated markets & institution.

Controller Controller Authorities Authorit

(GARIMA SHARMA)
Assistant Drugs Controller,
-cum- Licensing Authority,

HQ. Baddi, Distt. Solan, H.P.

No. HFW-H (Drugs)2024, Nahan, Dated the

M/s Systole Remedies Pvt Ltd, situated at Vill. Ogli, Kala Amb, Tehsil Nahan, Distt-Sirmour, 173030 H.P

Attested to Bo True Copy

Notary, PANCHKULA (Haryana)

29 MAR 2025

CS CamSo



🧿 Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

Format-V

Listofitemforwhichbidis quoted

SI N o.	Drug Code	Drug name	GST- HSN CODE	License number	Validity of License	First Date of approval of product	Reference page no. of docum ent submitt ed	Batch size	Shelf life of product as per annexur e-A	Deviation if any from the specification mentioned intender*
1	D100046	Atorvastatincalcium tabletIP40mg1*10strips	300490 99	MNB/06/434 & MB/04/435 DT. 13.11.2006	12.11.2026	25.11.2021	8-17	10lac tab	24months	None
	,	CefuroximeaxetilTablet IP500mg 1*4strips	99	MNB/06/434 & MB/04/435 DT. 13.11.2006	12.11.2026	07.09.2022	8-17	10lac tab	24months	None
3		Febuxostat40mgtab1*1 Ostrip	300490 99	MNB/06/434 & MB/04/435 DT. 13.11.2006	12.11.2026	25.11.2021	8-17	10lac tab	24months	None
4		Levecetram100mg/mlIn jection5mlVial	300490 99	MNB/06/434 & MB/04/435 DT. 13.11.2006	12.11.2026	25.11.2021	8-17	llac inj	24months	None
5		Leveracetam tab500mg1*10strips	300490 99	MNB/06/434 & MB/04/435 DT. 13.11.2006	12.11.2026	25.11.2021	8-17	5lac tab	24months	None
6		Meropenem250mginjdr ypowderwithwatercomb i pack 1*1dry powderVial		MNB/06/434 & MB/04/435 DT. 13.11.2006	12.11.2026	02.03.2022	8-17	llac inj	24months	None
7		MethylprednisoloneInje ction40mg/ml(1ml)1ml vial		MNB/06/434 & MB/04/435 DT. 13.11.2006	12.11.2026 N	25.11.2021	8-17	llac inj	36 months	None

Notary, PANCHKULA (Haryana) 29 MAR 2025

Page46of66



Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

Q	D020010	Pantaprazole40mg(tab)1	300490	MNB/06/434	12.11.2026	25.11.2021	8-17	10lac tab	24months	None
0		*10strip	99	&						
				MB/04/435						
				DT.						
				13.11.2006						
9	D340033	Thiamineinjection100m	300490	MNB/06/434	12.11.2026	23.12.2021	8-17	llac inj	24months	None
		g/ml,2mlVial	99	&						
				MB/04/435						
				DT.						
				13.11.2006						

*Ifbidderhasnot mentionedanydeviation,it willbetreatedfirmisacceptingandfulfillingalltheparametersand matchingallthe requirement/specifications/Terms.

SIGNATUREOFTHEAUTHORIZEDREPRESENTATIVE

NAME: RAVNEET SINGH

DESIGNATION DIRECTOR____

NAMEOFTHEFIRM/BIDDER: SYSTOLE REMEDIES PVT. LTD.___

STAMP OF THEFIRM/BIDDER_

NO ANDIA

Attested as Identified

Notary PANCHKULA (Haryana)

Page47of66

Health & Family Welfare Department, Himachal Pradesh DRUGS CONTROL ADMINISTRATION H.P. Office of Assistant Drugs Controller-cum-Drugs Licensing Authority

No. HFW-H(Drugs)288/06-

To

2885

Date 25/11/2021

M/s Systole Remedies Pvt. Ltd. Village- Ogli, Kala-Amb, Tehsil Nahan, District Sirmour, Himachal Pradesh- 173030.

Subject: -

Retention Letter for Licenses Nos. Form 25: MNB/06/434 and Form 28: MB/06/435 for the period from 13.11.2021 to 12.11.2026.

Sir,

Reference your letter No. SRPL/ADM/2021 dated 08.11.2021 regarding retention of drug manufacturing licenses as stated above.

In this regard, on the receipt of fee of Rs. 15000/- (Rupees Fifteen Thousand only) vide E-Challan No. A21K132901 dated 08.11.2021, for Retention and similarly, on the receipt of fee of Rs.250000/- (Rupees Two Lakh Fifty Thousand only) vide E-Challan Number A21K141413 dated 09.11.2021, for Additional Products, your Drugs Manufacturing Licenses Nos. MNB/06/434 and MB/06/435 on Form Nos. 25 & 28 Tablets, Capsules, Eye/Ear drops & Small Volume Parenterals (General Category), Tablets, Capsules, Oral Suspension & Small Volume Parenterals (Beta Lactam), Tablets & Small Volume Parenterals (Hormonal Category) granted on 13.11.2006 and valid upto 12.11.2021 have been retained w.e.f. 13.11.2021 to 12.11.2026 under Drugs and Cosmetics Rules (Tenth amended) Rules, 2017. The products retained with the license are enclosed.

Encls; Products list.

Controller-cumality of the state of the stat

(GARIMA SHARMA)
Assistant Drugs Controller,
-cum- Licensing Authority,

HQ Baddi, District Solan, H.P.

Endst. No. As above

01.

Copy to the Drugs Inspector, Nahan District Sirmaur H.P. for information

(GARIMA SHARMA)
Assistant Drugs Controller,
-cum- Licensing Authority,
HQ Baddi, District Solan, H.P.

Attested to partial copy

29 MAR 2025

NAUB SINGH Notary, PANCHKULA (Haryana)

FORM 28 (See Rule 76)

Licence to manufacture for sale or distribution of drugs specified in Schedules Conrolling - Cus C and C (1) [Excluding those specified in Sch. X]. Lisensing Authority Shimla (HLP.)

Number of licence and date of issue MB/06/435 Dated 13-11-2006.

1.M/S Systole Remedies (P) Ltd is hereby licensed to manufacture at the premises situated at Vill. Ogli Kala AmbTehsil Nahan, Distt Sirmour the following Drugs, being drugs specified in Schedules C and C (1) excluding those specified in Sch .X to the Drugs and Cosmetics Rules, 1945.

Name of drugs - as per list attached.

- Name of approved competent technical staff.
 - Mr. Rohini Raman Pathak B.Sc 1.

Manufacturing Chemist

Mr. Suchi Chabra

3. The licence authorizes the sale by way of wholesale dealing and storage for sale by the license of the drugs manufactured under the licence subject to the condition

applicable to licenses for sale. 4 The licence will be in force from ____ 3-11-2006 to 12-11-2011.

5. The licence is subject to the condition stated below and to such other conditions as may be specified in the Rules for the time being in force under the Drugs and Cosmetics Act, 1940.

Date of issue 13 -11-2006.

Signature Designation Usensing Authority

Shirela [H.F.

CONDITION OF LICENCE

1. This licence and any certificate of renewal in force shall be kept on the approved premises and shall be produced at the request of an Inspector appointed under the Drugs and Cosmetics Act, 1940.

2. If the licensee wisnes to undertake during the currency of the licence the manufacture of any drug specified in Schedules C and C (1) excluding those specified in Sch. X not included above, he should apply to the Licensing Authority for the necessary endorsement as provided in Rule 75(3). This licence will be deemed to

3. Any change in the competent technical staff shall be forthwith reported to the

4. (* * *)

5. The licensee shall inform the Licensing Authority in writing in the event of any change in the constitution of the firm operating under the licence. Where any change in the constitution of the firm takes place. The current licence shall be deemed to be valid for a maximum period of three months from the date on which the change takes place unless, in the meantime, a fresh licence has been taken from the Licensing Authority in the name of the firm with the changed constitution.

29 MAR 2025

Notary, PRINCHKULA (Hary

NO.HFW-H (Drugs) 288/66 HEALTH AND FAMILY WELFARE DEPARTMENT HIMACHAL PRADESH, SHIMLA-9)

To

M/s Systole Remedies (P) Ltd Vill. Ogli Kala AmbTehsil Nahan, Distt Sirmour.

Dated Shimla-9,

the

13-11-06

"bject:

Grant of Drugs Manufacturing Licenses.

Sir.

With reference to your application of dated 09-10-06 on the subject cited above.

Licence No. MNB/06/434 and LicenceNo. MB/06/435 for the sale of Drugs: -

- Biological Drugs special Products Specified in (i) Schedule C & C (I) of the Drugs Rules, 1945.
- Other than those Specified products C & C (I) of the (ii)

slare sent herewith duly granted/renewed.

Please acknowledge the receipt.

Yours Faithful

Drugs Controlling Cum-Licensing Authority

H.P. Shimla-9.



Notary, PANCHIKULA (Haryana)

29 MAR 2025



FORM 25 (See Rule 70)

LICENCE OF MANUFACTURE FOR SALE THOSE SPECIFIED [IN SCHEDULE C AND CONTAIN

Number of licence and date of issue MNB/06/434 Dated 13-11-2006.

Bruds Contolling Usensing Authority

Shimia [H.P.]

M/s Systole Remedies (P) Ltd is hereby licensed to manufacture the following categories of Drugs being drugs other than those specified in Schedule C& C (1) to the Drugs and Cosmetics Rules, 1945, on the premises situated at VIII. Ogli Kala AmbTehsil Nahan , Distt Sirmour under the direction and supervision of the following expert staff.

Expert staff (Name) (a)

Mr. Rohini Raman Pathak B.Sc 1.

2. Mr. Suchi Chabra

M.Sc

Manufacturing Chemist **Analytical Chemist**

(b) Name of drug as per list attached.

2. The licence authorises the same by way of wholesale dealing and storage for sale by the Licensee of the drugs manufactured under the licence, subject to the condition applicable to licence for sale.

The licence shall be in force from 12-11-2006 to 12-11-2011.

4. The licence is subject to the conditions stated below and to such other conditions as may be specified in the rules for the time being in force under the Drugs and

Date 13 -11-2006.

Signature Designation

Canrolling - Cust Lisensing Authority Shimla (H.P.)

CONDITION OF LICENCE

This licence and any certificate of renewal in force shall be kept on the approved mises and shall be produced at the request of an inspector appointed under the Drugs and Cosmetics Act, 1940.

Any change in the expert staff named in the licence shall be forthwith reported to the Licensing Authority.

If the licensee wants to manufacture for sale additional items of drugs not include above he should apply to the Licensing Authority for the necessary endorsement as provided in Rule 69(5). This licence will be deemed to extend to the categories so endorsed.

4. The sale by way of wholesale dealing of drugs manufactured under this licence shall be covered by a warranty either in Form 22 or Form 23 to the effect that the drugs sold to do not in any way contravene the provisions of section 18 of the Drugs and Cosmetics Act, 1940.

The Licence shall inform the licensing Authority in writing in the event of any change in the constitution of the firm operating under the licence. Where any change in the constitution of the firm takes place, the current licence shall be deemed to be valid for a maximum period of three months from the date on which the change takes place unless in the meantime, a fresh licence has been taken from the Licensing Authority in the name of the firm with the

Notary, PANCHIKULA (Haryana)

29 MAR 2025

gemedi

PART XII STANDARDS

1124—Standards of drugs.--

(1) Drugs included in the Indian Pharmacopoeia--

- (a) The standards for identity, purity and strength shall be those as may be specified in the edition of the Indian Pharmacopoeia for the time being in force.
- (b) In case the standards for identity, purity and strength for drugs are not specified in the edition of the Indian Pharmacopoeia for the time being in force but are specified in the edition of the Indian Pharmacopoeia immediately preceding, the standards for identity, purity and strength shall be those occurring in such immediately preceding edition of the Indian Pharmacopoeia.

(2) For other drugs--


- (a) The standards for identity, purity and strength shall be those as may be specified in the edition of the official pharmacopoeia, for the time being in force, of any country to which the drug claims to comply with,
- (b) In case the standards for identity, purity and strength for drugs are not specified in the edition of such official pharmacopoeia for the time being in force, but are expected in the edition immediately preceding, the standards for identity, purity and strength shall be those occurring in such immediately preceding edition of such official pharmacopoeia to which the drug claims to comply with.
- (c) For drugs for which standards are not included in the edition of the official pharmacopoeia, for the time being in force, of any country or in edition immediately preceding, but included in the official compendia of drug standards, namely, the British Pharmaceutical Codex or the National Formulary of the United States, for the time being in force, to which the drug claims to comply with.

²124A. Standards for veterinary drugs—For drugs intended for veterinary use, the standards shall be those given in the current edition for the time being in force of the ³[British Pharmacopoeia (Veterinary)].

⁴124-B Standards for patent or proprietary medicines: -- The standards for patent or proprietary medicines shall be those laid down in Schedule V and such medicines shall also comply with the standards laid down in the Second Schedule to the Act.

Amended by G.O.I. Notification No. GSR 19 dt 7.1.978.

³Subs. by G.O.I. Notification No. GSR 647(E) dt 28.10.1998.





Amended by G.O.I. Notification No. F. 1-6/62-D dt 2.7.1969.

14A

No. HFW-H (Drugs) 228/06 HEALTH AND FAMILY WELFARE DEPARTMENT HIMACHAL PRADESH

To

F9 JAN 2023

M/s Systole Remedies Pvt. Ltd., Village Ogli, Tehsil Nahan, Kala Amb, Distt. Sirmour (H.P) 173030

Subject:-

Change in Pharmacopoeial reference.

This is to inform you that the products / salts, which were previously claimed as BP/USP/Ph. Eur. and in other Pharmacopoeial references or were not official in any other pharmacopoeia, but now have been included in IP-2022, may please be claimed as per IP-2022 on your label claim w.e.f. 01.12.2022.

(GARIMA SHARMA)

Asstt. Drugs Controller,
(Garima Sharting) sing Authority
Asstt. Drugs Baddi Distr. Solan

Asstt. Drigs Badd Dist. Solan Himachal Pradesh, -cum-Licensing Authority,

H.Q. Baddi, Distt. Solan-173205







HFW-H(Drugs)/288/06 Health and Family Welfare Department Drtug Control administration HP

Office of Asstt. Drugs Controller-cum-Licensing Authority, CMO Office Complex at Nahan (H.Q.) Distt. Sirmour (H.P.), 173001 INDIA

List of Additional Products Approved to be manufactured at M/S Systole Remedies Pvt. Ltd. Village-Ogli, Tehsil-Nahan, Kala-Amb, Distt. Sirmour, H.P.-173030, India. Having License No Form-25: MNB/06/434 & Form-28: MB/06/435, Valid up to 12/11/2026. Pack Size as per schedule P-1 of Drugs and Cosmetic Rule 1945

Sr. No.	DOSAGE FORM	COMPOSITION	SPEC.	QTY.		REFERENCE	
7	L-Alanyl-L-Glutamin	e Each 100 ml contains:		1			
	Solution for Infusion	L- Alanyl-L-Glutamine (L-Alanine 8.20g L-Glutamine 13.46g)		20	Gm	Pace Biotech Ponta Sahib	
		Water for Injection	IP	q.s.			
8	Phiamine Injection	I Publish and the second of th					
	2.2	Each ml contains:					
	0340033	Thiamine Hydrochloride	IP	100	mg	Pace Biotech,	
************************	0340033	Water for Injection	IP	q.s.	1.115	Ponta Sahib	
)	Aciclovir						
	Intravenous Infusion	Each vial contains:				IP 2018	
	IP IP	Aciclovir Sodium (sterile) (Lyophilized)	IP			IF 2018	
		Eq. to Aciclovir		500	mg		
0	Lactitol Monohydrate	D-116					
	and Ispaghula Husk Granules	Each 15 gm granules contains:					
		Lactiol Monohydrate	BP	10	gm		
		Ispaghula Husk	IP	3.5	gm	DCGI approval	
		Excipients		q.s.		21.11.2005	
		Colour: Approved colour used			7		
1	Acetylcysteine	Each ml contains:					
	Injection BP	Acetylcysteine	-			BP 2013	
			BP	200	mg		
		Water for Injection	IP	q.s.			
)	Cerebroprotein	E de la					
	Hydrolysate Injection	Each vial contains:					
	(typhollised)	CerebroproteinHydrolysate 2100 mg (Approximately) Eq. to Nitrogen		60	mg	DCGI approval: 9.11.2010	
		Excipients		q.s.	mg		
	DI .						
	Phytomenadione	Each 0.5 ml contains:					
	Injection	Phytomenadione	IP	1	ma	Pace Biotech,	
		Water for Injection TIVE/GUIDELINES	IP (1	mg	Ponta Sahib	

NAISSINGH

PROVIDE (NO!!)

* PROVIDE (11-03-2039)

GOLDE 11-03-2039

CT 1940 RULES 1945 MADE THERE UNDER AS AMENDED

Attested to Be True Copy

Notary, PANCHIVLA (Haryan

(GARIMA SHARMA)
Asstt. Drugs Controller,
-cum-Licensing Authority
HQ. Baddi, Distt. Solan

Himachal Pradesh

29 MAR 2025

B

NO. HFW-H (DRUGS)/330/06-VOL-II-

Health and Family Welfare Department (H.P.)
Drugs Control administration HP
Office of Asstt. Drugs Controller-cum-Licensing Authority,
CMO Office Complex at Nahan (H.Q.)
Distt. Sirmour (H.P.), 173001 INDIA

LIST OF RETETION PRODUCTS APPROVED TO BE MANUFACTURED AT M/S SYSTOLE REMEDIES PVT. LTD. VILLAGE-OGLI, TEHSIL- NAHAN, KALA-AMB, DISTT. SIRMOUR, H.P.-173030, INDIA. HAVING LICENSE NO FORM-25: MNB/06/434 & FORM-28: MB/06/435, RETAINED UP TO 12.11.2026. (PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETIC RULE 1945)

Sr. no.	Generic Name	Composition	Pharma. Ref	Strength	Reference
137.	Esomeprazole for Injections 40mg For IV use	Each Vial contains: Esomeprazole Sodium Sterile Lyophilized powder Eq. to Esomeprazole This pack contains 10ml ampoule of sodium Chloride Inj.IP 0.9% w/v	IH	40mg	20.09.202
138.	Pantoprazole Tablets IP	Each enteric coated Tablet contains: Pantoprazole Sodium Eq. to Pantoprazole Excipients Approved color used	IP .	40mg q.s.	20.09.2021
139.	Pantoprazole EC & Domperidone SR Capsules 40mg+30mg	Each hard gelatin capsule contains: Pantoprazole sodium (As enteric coated pellets) Eq. to Pantoprazole Domperidone (As sustained release pellets) Excipients Approved color used in hard gelatin capsules	IP IP	40mg 30mg q.s.	20.09.2021
140.	Rabeprazole EC & Domperidone SR Capsules 20mg+30mg	Each hard gelatin capsule contains: Rabeprazole sodium (As enteric coated pellets) Eq. to Rabeprazole Domperidone (As sustained release pellets) Excipients Approved color used in hard gelatin capsules	IPON STATE OF THE PROPERTY OF	20mg 30mg q/s.	20.09.2021
141.	Omeprazole capsules IP 20mg	Each Hard Gelatin capsule contains: Omeprazole Sodium (As enteric coated pellets) Excipients Approved color used in hard gelatin capsules		q.s.	20.09.2021 Opy

APPROVALS ARE SUBJECT TO THE COMPLIANCE OF ALL DIRECTIVE/GUIDELINES ISSUED BY DCGI/CDSCO FROM TIME TO TIME & COMPLIANCE OF DRUGS & COSNETICS ACT 1940 RULES 1945 MADE THERE UNDER AS AMENDED FROM TIME TO TIME

FIRM WILL NOT MANUFACTURE ANY RETAINED

ARIMA SHARMA)
Acist Drugs Controller
Conn-Licensing Authorit
Baddi, Diett. Scien
Chachal Pradesh

29 MAR 2025

Yuthorised

Inject the reference solution and the test solution.

Calculate the content of C₁₆H₁₄F₂N₃NaO₄S.

Storage. Store protected from light and moisture, at a temperature not exceeding 30°. Considerating the forecast and it is the contract of the property of the contract of the contr

Pantoprazole Gastro-resistant Tablets

Pantoprazole Tablets; Pantoprazole Sodium Gastroresistant Tablets; Pantoprazole Sodium Tablets

Pantoprazole Gastro-resistant Tablets contain an amount of Pantoprazole sodium equivalent to not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of pantoprazole, C16H15F2N3O4S. They are made gastro-resistant by enteric-coating or by other means.

Usual strenth. 20 mg; 40 mg.

Identification

A. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the principal peak in the chromatogram obtained with the reference solution.

B. When examined in the range 230 nm to 350 nm (2.4.7), a 0.001 per cent w/v solution in methanol shows absorption maxima at about 289 nm.

Tests

Dissolution (2.5.2).

NOTE - Prepare the solutions immediately before use. Protect the solutions from light.

A. Apparatus No. 2 (Paddle),

Medium. 1000 ml of 0.1 Mhydrochloric acid.

Speed and time. 100 rpm and 2 hours.

Determine by liquid chromatography (2.4.14).

Test solution. Withdraw the medium completely and disperse the intact tablet in 100 ml of the mobile phase and filter.

Reference solution. Dissolve a weighed quantity of pantoprazole sodium IPRS in the mobile phase and dilute with the mobile phase to obtain a solution having a known concentration similar to the test solution.

Use chromatographic system as described under Assay.

Inject the reference solution and the test solution.

Calculate the content of C16H15F2N3O4S released in the acid medium by subtracting the content of C16H15F2N3O4S in the test solution from the total content of Pantoprazole C₁₆H₁₅F₂N₃O₄S determined in the Assay.

Complies with the acceptance criteria given under acid stage.

B. Apparatus No. 2 (Paddle),

Medium. 1000 ml of phosphate buffer pH 6.8, Speed and time. 75 rpm and 45 minutes.

Transfer another 6 tablets and run the apparatus for 2 hours in 0.1 M hydrochloric acid. Decant the medium without losing the tablets, add phosphate buffer pH 6.8 and run the apparatus for 45 minutes. Withdraw a suitable volume of the medium and filter.

Determine by liquid chromatography (2.4.14).

Solvent mixture. Equal volumes of phosphate buffer 6.8 and 0.5 M sodium hydroxide.

Test solution. Dilute 5.0 ml of the filtrate to 10.0 ml with 0.5M sodium hydroxide.

Reference solution. Dissolve 20 mg of pantoprazole sodium IPRS in 30 ml of 0.02M sodium hydroxide, with the aid of ultrasound, add 2 ml of acetonitrile and dilute to 50.0 ml with 0.02M sodium hydroxide. Dilute a portion of the solution with the solvent mixture to obtain a solution having a known concentration similar to the expected concentration of the test solution.

Use chromatographic system as described under Assay. Inject the reference solution and the test solution.

Calculate the content of C₁₆H₁₅F₂N₃O₄S in the medium.

Q. Not less than 75 per cent of the stated amount of C16H15F2N3O4S.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

NOTE-Prepare the solutions immediately before use. Protect the solutions from light.

Test solution. Weigh and powder 20 tablets. Weigh a quantity of powder containing about 20 mg of Pantoprazole Sodium, disperse in 100 ml of the mobile phase and filter.

Reference solution. A 0.02 per cent w/v solution of pantoprazole sodium IPRS in the mobile phase.

Chromatographic system

- stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),

- mobile phase: a mixture of 50 volumes of buffer solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 1 g of hexane sulphonic acid sodium salt in 1000 ml of water, adjusted to pH 7.3 with 1 M sodium hydroxide and 50 volumes of acetonitrile,
- flow rate: 1.5 ml per minute,
- spectrophotometer set at 290 nm,
- injection volume: 10 µ1.



3189

HFW-H(Drugs)/288/06 Health and Family Welfare Department Himachal Pardesh

List of Retention Product approved to be manufactured at M/S Systole Remedies Pvt. Ltd. Village-Ogli, Tehsil-Nahan, Kala-Amb, Distt. Sirmour, H.P.-173030, India. Having License No Form-25: MNB/06/434& Form-28: MB/06/435, Retained up to 12/11/2026. Pack Size as per schedule P-1 of Drugs and Cosmetic Pule 1045

No.	GENERIC NAME DOSAGE FORM	COMPOSITION	SPEC.	QTY.	UNIT	REFERENCE :			
		Each Vial contains:							
	Dexamethasone Sodium	Dexamethasone Sodium Phosphate Equivalent to Dexamethasone Phosphate	e IP	4	mg	Approved on 12/05/2021			
22.	Phosphate Injection IP 4mg	Methyl Paraben (as Preservative)	IP	0.18% w/v					
		Propyl Paraben (As Preservative)	IP	0.02% w/v					
		Water for Injection		q.s.					

		Each Vial contains:				T and the same and			
	Methylprednisolone Acetate Injection BP 40mg FOR IM USE ONLY	Methylprednisolone Acetate Polyethylene Glycol	BP	40	mg	Approved on			
23.		3350-Sodium Chloride Myristylgamma-picolinium chloride		0,2	mg	12/05/2021			
	D1600	Water for Injection		q.s.					
24.	Albendazole Tablets IP 400 mg	Each uncoated tablet contains: Albendazole Excipients Approved Colours used.	TIP	400	mg q.s.	Approved on 12/05/2021			
		Each film coated tablet contains: Desloratadine							
5.	Desloratadine & Montelukast Tablets	Montelukast Sodium	IP	5	mg mg	Approved on 12/05/2021			
5.		Equivalent to Montalukest				12(03/2021			
5.	Montelukast Tablets (5mg+10mg)	Equivalent to Montelukast Excipients Approved Colours used	6T	10	q.s.				
5.			6T/ NARD		q.s.				
5.		Excipients Approved Colours used. Each film coated tablet contains:*	Panginal-	MOH Zuoro Ausso	q.s.				
6.		Approved Colours used.	Panginal-	1011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Approved on 12/05/2021			

ALL PRODUCT APPROVILS AS ABOVE ARE VALID SU COMPLIANCE OF ALL KIN

MANUFACTURER WINCH A TIME TO TIME & COMPLIANCE OF DRUGS RULES 1948 MADE THERE UNDER, INCLUS FROM TIME TO TIME

(GAKINA SHAKNA) Asstt. Drugs Controller. -cum-Licensing Authority HQ. Baddi, Distt. Solan Himachal Pradesh

29 MAR 2025

HFW-H(Drugs)/288/06 Health and Family Welfare Department

Himachal Pardesh

MB/06/435, Retained up to 12/11/2026. Pack Size as per schedule P-1 of Drugs and

	GENERIC NAME DOSAGE FORM	COMPOSITION	SPEC.	QTY.	UNIT	REFERENC	
1		Each ml contain	ns:				
1		Clindamycin	I.P	150	mg		
Province of Communications and American Communications (Income	Clindamycin &Benzyl Alcohol Injection	Benzyl Alcohol	I.P	0.945	%	Approved On: 29.07.2021	
<u>ー</u>		Each Vial contains:					
-		Meropenem	IP	T	***************************************	Approved On	
	Meropenem Injection IP	Equiant to Meropenem (Anhydrous)		1	gm	29.07.2021	
		Water for Injection IP					
		THE TOT THE COURT					
		Each Vial contains:					
-		Meropenem	IP	· · · · · · · · · · · · · · · · · · ·		Approved On : 29.07.2021	
	Meropenem Injection IP	Equiant to Meropenem (Anhydrous)		500	mg	29.07.2021	
-		Water for Injection	IP		q.s.	and the second s	
			20000000000000000000000000000000000000			gg-00-2	
		Each Vial contains:		***************************************		Approved On	
	Meropenem Injection IP	Meropenem	IP	250	mg	29.07.2021	
	Solve 94	Equiant to Meropenem (Anhydrous)	IP		q.s.		
	D040094	Water for Injection	1 IF	***************************************			
	y						
		Each Vial contains:	IP			Approved On: 29.07.2021	
4.	Meropenem Injection IP	Meropenem Equiant to Meropenem (Anhydrous)	Atteste	d tt25g T		29.07.2021	
		Water for Injection	IP A	P	q.s.	AND THE RESIDENCE OF THE PROPERTY OF THE PROPE	
			1/	MAIS SING	U		
		Each Vial contains:	Notary P.	AVICHKULA	(Harvano)	Approved On:	
	Cefuroxime Injection IP	Cefuroxime Sodium	A Commence of the Commence of	1.5		29.07.2021	
5.	Ceruroxime injection if	Equiant to Cefuroxime	IP.	1.3	gm q.s.		
		Water for Injection	In the second	1/4			
		Each ml contains:					
		Cities 12 1 Partie	AIP /	3/			
		Eq. to Citicoline	15	2/250	mg	Approved On:	
6.	Citicoline Injection IP	Methyl Paraben	IP	0.1	%	29.07.2021	
		(As preservative)	IP	0.01	%		
		Propyl Paraben (As preservative)	11	0.01	70	us an	
PRO LL P OMP	M WILL NOT MANUFACTURE A DUCT IF IT FALLS UNDER DAINIFD: MEDDIGT TO FALLS UNDER DAINIFD: MEANOR OF FALL MISLS OF SET MEACURER WACH ARE INCURED TO TIME & COMPLIANCE OF DRU-	NY RETAINED USE OFFICE TO THE	F H	GARIMA sstt. Drug um-Licen Q. Baddi, imachai P	Sing Auth Dist. Soi	pority	



NO. HFW-H (DRUGS)/330/06-VOL-II-Health and Family Welfare Department (H.P.) Drugs Control administration HP Office of Asstt. Drugs Controller-cum-Licensing Authority, CMO Office Complex at Nahan (H.Q.) Distt. Sirmour (H.P.), 173001 INDIA

LIST OF RETETION PRODUCTS APPROVED TO BE MANUFACTURED AT M/S SYSTOLE REMEDIES PVT. LTD. VILLAGE-OGLI, TEHSIL- NAHAN, KALA-AMB, DISTT. SIRMOUR, H.P.-173030, INDIA. HAVING LICENSE NO FORM-25: MNB/06/434 & FORM-28: MB/06/435, RETAINED UP TO 12.11.2026. (PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETIC RULE 1945)

Sr.	Generic Name	Composition	Pharma. Ref	Strength	Reference
228.	Cefuroxime Axetil tablets IP 250mg	Each film coated tablet contains: Cefuroxime Axetil Eq. to Cefuroxime Excipients Approved color used	IP	250mg q.s.	20.09.202
229.	Cefuroxime Axetil tablets IP 500mg	Each film coated tablet contains: Cefuroxime Axetil Eq. to Cefuroxime Excipients Approved color used	IÞ	500mg q.s.	20.09.2021
230.	Cefuroxime Axetil for oral Suspension USP 125mg/ml	Each 5ml contains: Cefuroxime Axetil Eq. to Cefuroxime Excipients Approved color used	IP	125mg q.s	20.09.2021
231.	Cefuroxime and Clavulanic acid Tablets 500mg+ 125mg	Each film coated tablet contains: Cefuroxime Axetil Eq. to Cefuroxime Potassium Clavulanate Diluted Eq. to Clavulanic Acid Excipients Approved color used	IP IP	500mg .125mg q.s.	20.09.2021
232.	Ebastine tablets JP 10mg	Each film coated tablet contains: Ebastine Excipients Approved color used	JP	10mg q.s.	20.09.2021
233.	Ebastine tablets JP 20mg	Each film coated tablet contains: Ebastine Excipients Approved color used	IP X	20mg q.s.	20.09.2021
234.	Fexofenadine Hydrochloride tablets IP 120mg	Each film coated tablet contains: Fexofenadine Hydrochloride Excipients Approved color used	IP	120mg q.s.	20.09.2021

APPROVALS ARE SUBJECT TO THE COMPLIANCE OF ALL DIRECTIVE/GUIDELINES ISSUED BY DCGI/CDSCO FROM TIME TO TIME & COMPLIANCE OF DRUGS & COSMETICS ACT 1940 RULES 1945 MADE THERE UNDER AS AMENDED FROM TIME TO TIME

FIRM WILL NOT MANUFACTURE AN CRETAINED PRODUCT IF IT FALLS UNDER BANNED LIST OF DRUGS

GARIMA SHARMA)

Asstt Drugs Controller -cum-Licensing Authority 10. Baddi, Distt, Sofnn

Attested to the Property

Notary PANCHKULA (Harvana)

29 MAR 2025



HFW-H(Drugs)/288/06 Health and Family Welfare Department Himachal Pardesh

List of Retention Product approved to be manufactured at M/S Systole Remedies Pvt. Ltd. Village-Ogli, Tehsil-Nahan, Kala-Amb, Distt. Sirmour, H.P.-173030, India. Having License No Form-25: MNB/06/434 & Form-28: MB/06/435, Retained up to 12/11/2026. Pack Size as per schedule P-1 of Drugs and Cosmetic Rule 1945

Sr. No.	GENERIC NAME DOSAGE FORM		COMPOSITION		SPEC.	QT	Υ. ι	INIT	REFERENÇE
			BepotastineBesilate				1.5	%w/	VI
58	BepotastineBesilateOphthalmic		Potassium Sorbate			IP 0.2			Approved On
30	Solution		Sterile Aqueous Vehic	ele		1.1	q.s		2.9.2021
		Each	Uncoated dispersible t	ablet cont	ains:				
59	Ketorolac Tromethamin	Ketoro	olac Tromethamin		I	Р	10	mg	Approved On:
,	Dispersible Tablets	Excipi	ents					q.s.	2.9.2021
		Appro	ved Colour Used						
			Filmcoated tablet cont	ains:					
60	Levetiracetam tablets		racetam		U	SP	250	mg	Approved On:
	USP	Excipi				q		q.s.	2.9,2021
		Appro	ved Colour Used						
		Each	Filmcoated tablet cont	ains:					
			racetam			SP	500	mg	Approved On :
61	Levetiracetam tablets	Excipi						q.s.	2.9.2021
	USP D2 80057	in the second se	ved Colour Used						
		Tibbio							
		Each	ilmcoated tablet contains:						
62	Levetiracetam tablets USP	Leveti	racetam		USP 7		750	mg	Approved On:
V -		Excipi	•				q.s.	2.9.2021	
		Appro	ved Colour Used						
		Each	Filmcoated tablet cont	THE REAL PROPERTY AND ADDRESS OF THE PERSON NAMED AND POST OF THE PERSON N					
63	Levetiracetam tablets	Leveti	racetam	STAR	U	SP	1000	mg	Approved On:
0.5	USP	Excipi			1	1		q.s.	2.9.2021
		Appro	ved Colour Used //	NUMBER	1 /				
				panchauls (1)					1
			Filmcoated controlled			rtains			
	0 1/ 1/ 1/ 222	Lancoura sus consumos consumos	n Valproate).\	BP		333	mg	
	Sodium Valproate 333	-	oic acid	VER	Usi		145	mg	Approved On:
64	mg & Valproic acid 145 mg Tablets		ogether correspond to S	od um					2.9.2021
	ing radicts	Annual Contract of the Contrac	pate BP 500 mg						
		Excipi	ved Colour Used	······································				q.s.	
		Ttppro	ved Colour Osed	<u> </u>			7		9 - 250
	FIRM WILL NOT MANUF	ACTURE	ANY RETAINED	Car		100	Car		925112011
	PRODUCT IF IT FALLS UND		LIST OF DRUGS Comedia	3500	1.	(OA	RIMA	SHAR	
			28/10	XXI		ASS	II. Drug	s Cont	Cler
	ALL PRODUCT APPROVAL	9 49 400	THE WAS RECORD	Tue / E/		Tul	Baudi,	sing A	thority
	COMPLHANCE OF ALL ION	Comments of the Comments of th	A SELENIAL PROPERTY OF THE PRO	1.1344		7763	Print Charles and Charles	70 MAR 197	

MANUFACTURER STRICH ARE IDSUED BY DESTRUCTION TO THE S CONPLIANCE OF DRIESS & RULES 1945 MADE THERE UNDER, INCLUDING AN

FROM TIME TO TIME

Page No.28 of

Notary, PANCHKULA (Haryana)

NO. HFW-H (DRUGS)/330/06-VOL-II-

Health and Family Welfare Department (H.P.)

Drugs Control administration HP

Office of Asstt. Drugs Controller-cum-Licensing Authority,

CMO Office Complex at Nahan (H.Q.) Distt. Sirmour (H.P.), 173001 INDIA

LIST OF RETETION PRODUCTS APPROVED TO BE MANUFACTURED AT M/S SYSTOLE REMEDIES PVT. LTD. VILLAGE-OGLI, TEHSIL- NAHAN, KALA-AMB, DISTT. SIRMOUR, H.P.-173030, INDIA. HAVING LICENSE NO FORM-25: MNB/06/434 & FORM-28: MB/06/435, RETAINED UP TO 12.11.2026. (PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETIC RULE 1945)

Sr. no.	- Concretiante	Composition	Pharma. Ref	Strength	Reference
	Injection IP 75mg/ml For IM use only	Each ml contains: Diclofenac Sodium Benzyl Alcohol (As preservative) Water for Injection	IP IP	75mg 4% v/v	20.09.202
372	. Clindamycin	Fach hard Calai C	IP	q.s.	
	Hydrochloride Capsules IP 150mg	Each hard Gelatin Capsule contains: Clindamycin Hydrochloride Eq. to Clindamycin Excipients Approved color used in hard gelatin capsules	IP	150mg q.s.	20.09.2021
373.	25mg	Each hard Gelatin Capsule contains: Indomethacin Excipients Approved color used in hard gelatin capsules	IP .	25mg q.s.	20.09.2021
374.	Febuxostate Tablets 40mg 260003	Each uncoated tablet contains: Febuxostate	IH	40mg	20.09.2021
375.	Febuxostate Tablets	Excipients		q.s.	
7/	80mg	Each uncoated tablet contains: Febuxostate Excipients		80mg	20.09.2021
76.	Febuxostate Tablets 120mg	Each uncoated tablet contains: Febuxostate Excipients	IH	q.s. 120mg	20.09.2021
77.	Clarithromycin Tablets 500mg	Each film coated tablet contains: Clarithromycin Excipients Approved color word	333	9.s. 500mg 9.s.	20.09.2021
78.	Fluconazole tablets IP 300mg	Each uncoated tablet contain Fluconazole Excipients	IP () 3	300mg	20.09.2021

APPROVALS ARE SUBJECT TO THE COMPLIANCE OF ALL DIRECTIVE/GUIDELINES ISSUED BY DCGL/CDSCO FROM TIME TO TIME & COMPLIANCE OF DRUGS & COSMETICS ACT 1940 RULES 1945 MADE THERE UNDER AS AMENDED FROM TIME TO TIME

48

FIRM WILL NOT MANUFACTURE ANY RETAIN A AGDUCT IF IT FALLS UNDER BANNED LIST OF DRUGS

GARIMA SHARMA)

Pasti Drugs Controlle -c-m-Licensing Authority HQ. Baddi, Diett. Solan

Attested to Hal Pradesh 29 MAR 2025

Notary, PAN

NO. HFW-H (DRUGS)/330/06-VOL-H-Health and Family Welfare Department (H.P.) Drugs Control administration HP Office of Asstt. Drugs Controller-cum-Licensing Authority, CMO Office Complex at Nahan (H.Q.) Distt. Sirmour (H.P.), 173001 INDIA

LIST OF RETETION PRODUCTS APPROVED TO BE MANUFACTURED AT M/S SYSTOLE REMEDIES PVT. LTD. VILLAGE-OGLI, TEHSIL- NAHAN, KALA-AMB, DISTT. SIRMOUR, H.P.-173030, INDIA. HAVING LICENSE NO FORM-25: MNB/06/434 & FORM-28: MB/06/435, RETAINED UP TO 12.11.2026. (PACK SIZE AS PER SCHEDULE P-1 OF DRUGS AND COSMETIC RULE 1945)

Sr. no.	Generic Name	Composition	Pharma.	Strength	Reference
48.	20mg	Each film coated tablet contains: Rosuvastatin calcium Eq. to Rosuvastatin Excipients Approved color used	Ref IP	20mg q.s.	20.09.2021
49.	Atorvastatin tablets IP 10mg	Each film coated tablet contains: Atorvastatin calcium Eq. to Atorvastatin Excipients Approved color used	IP	10mg q.s.	20.09,2021
<i>5</i> 0.	Atorvastatin tablets IP 20mg	Each film coated tablet contains: Atorvastatin calcium Eq. to Atorvastatin Excipients Approved color used	IP .	20mg q.s.	20.09.2021
	Atorvastatin tablets IP 40mg	Each film coated tablet contains: Atorvastatin calcium Eq. to Atorvastatin Excipients Approved color used	IP	40mg q.s.	20.09.2021
52.	Metoprolol Succinate (ER) & Telmisartan Tablets 25mg+ 40mg	Each film coated tablet contains: S(-) Metoprolol Succinate Eq. to S(-) Metoprolol (as extended release) Telmisartan Excipients Approved color used	IP IP	25mg 40mg q.s.	20.09.2021
53.	Metoprolol Succinate (ER) & Telmisartan Tablets 50mg+ 40mg	Each film coated tablet contains as SI	IP *	50mg 40mg q.s.	20.09.2021

APPROVALS ARE SUBJECT TO THE COMPLIANCE OF ALL DIRECTIVE/GUIDELINES ISSUED BY DCGI/COSCO FROM TIME TO TIME & COMPLIANCE OF DRUGS & COSMETICS ACT 1940 RULES 1945 HADE THERE UNDER AS AMENDED FROM TIME TO TIME

FIRM WILL NOT MANUFACTURE AN PRODUCT IF IT FALLS UNDER BANNEDL

ARIMA SHARMA)
About Drugs Controller,
Clun-Licensing Authority

Q. Baddi, Distt. Solan Emachal Pradesh

Attested to Berthan Copy

29 MAR 2025

Notary, PANCHKULA (Haryana)



HFW-H(Drugs)/288/06 Health and Family Welfare Department Himachal Pardesh

List of Retention Product approved to be manufactured at M/S Systole Remedies Pvt. Ltd. Village-Ogli, Tehsil-Nahan, Kala-Amb, Distt. Sirmour, H.P.-173030, India. Having License No Form-25: MNB/06/434 & Form-28: MB/06/435, Retained up to 12/11/2026. Pack Size as per schedule P-1 of Drugs and *Cosmetic Rule 1945

No.	GENERIC NAME DOSAGE FORM	COMPOSITION	SPE	C. (QTY.	UNIT	REFERENÇE
		Each ml contains:		•	***************************************		
70.	Levetiracetam Injection	Levetiracetam	**************************************	USP	100	T	
	The state of the s	Excipients		160	100	mg	Approved On 20.9.2021
	USP D280050	Approved Colour Used				q.s.	20.9.2021
		Each ml containe:		•			
		TimololMaleate		ID	~ y ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
71	TimololEye Drop IP	Eq. to Timolol		IP	0.5		
	Timololicye Diop in	Benzalkonium Chloride	***************************************	IP	0.5	%w/v %v/v	Approved On 20.9.2021
		(As Preservative)		11	0.01	%0V/V	20.9.2021
		Sterile Aqueous Vehicle			q.s.		
	*************************************			100			
		Each ml Contains:					
	Methylcobalamine	Methylcobalamine		IP	500	maga	
72	Injection	Benzyle alcohol		IP	2	mcg %v/v	Approved On:
		(as Preservative)				70171	20.9.2021
		111	**************************************	***************************************			
		Water for Injection	*	IP		q.s.	
	Noradrenaline Bitartrate	Each ml Contains:		IP		q.s.	•
73	Injection IP	Each ml Contains: Noradrenaline Bitartrate		IP IP	2		Approved On:
7 3	Injection IP (Sterile Noradrenaline	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg)			2	q.s.	Approved On: 20.9.2021
73	Injection IP	Each ml Contains: Noradrenaline Bitartrate			2		
73	Injection IP (Sterile Noradrenaline	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg)		ΙΡ	2	mg	
7 3	Injection IP (Sterile Noradrenaline	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg) Water for Injection	ach 5 ml co	IP IP		mg	
	Injection IP (Sterile Noradrenaline concentrate)	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg)		IP IP	ls:	mg q.s.	
73	Injection IP (Sterile Noradrenaline concentrate) Linezolid for oral	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg) Water for Injection After reconstitution upto 30ml, E		IP IP		mg q.s.	20.9.2021 Approved On :
	Injection IP (Sterile Noradrenaline concentrate)	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg) Water for Injection After reconstitution upto 30ml, E. Linezolid Excipients		IP IP ontair IP	100	mg q.s.	20.9.2021
	Injection IP (Sterile Noradrenaline concentrate) Linezolid for oral	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg) Water for Injection After reconstitution upto 30ml, E. Linezolid Excipients Flavoured syrupy base		IP IP Ontain IP	100 27a	mg q.s.	20.9.2021 Approved On :
	Injection IP (Sterile Noradrenaline concentrate) Linezolid for oral	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg) Water for Injection After reconstitution upto 30ml, E. Linezolid Excipients		IP IP ontair IP	100 27a	mg q.s.	20.9.2021 Approved On :
	Injection IP (Sterile Noradrenaline concentrate) Linezolid for oral	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg) Water for Injection After reconstitution upto 30ml, Excipients Flavoured syrupy base Approved co	plour sed	IP IP Ontain IP	100 27a	mg q.s.	20.9.2021 Approved On :
4	Injection IP (Sterile Noradrenaline concentrate) Linezolid for oral suspension Cefadroxil Dispersible	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg) Water for Injection After reconstitution upto 30ml, E. Linezolid Excipients Flavoured syrupy base	plour sed	IP IP Ontain IP	100	mg q.s. mg q.s. q.s.	20.9.2021 Approved On: 20.9.2021
4	Injection IP (Sterile Noradrenaline concentrate) Linezolid for oral suspension	Each ml Contains: Noradrenaline Bitartrate Eq. to Noradrenaline 1mg) Water for Injection After reconstitution upto 30ml, Excipients Flavoured syrupy base Approved co	plour sed	IP IP Ontain IP	100	mg q.s.	20.9.2021 Approved On :

FIRM WILL NOT MANUFACTURE ANY RETAINED PRODUCT IF IT FALLS UNCER BANK

ALL PRICESOT APPROVALS AS COMPLIANCE OF ALL KINDS OF MANUFACTURER WHICH AND TIME TO TIME & COMPLIANCE & RULES 1945 MADE THERE UNDER, IN FROM TIME TO TIME

29 MAR 2025

Thorised S

Attested to Be Tr

NAIB SINGH

(GARIMA SHARMA) Assit. Drugs Controller, -cum-Licensing Authority HQ. Baudi, Distt. Solan Umachal Pradesh

Page No 30 of

HF W-H (Drugs) 288/00 HEALTH AND FAMILY WELFARE DEPARTMENT HIMACHAL PRADESH

MARKET STANDING CERTIFICATE

This is to certify that M/s Systole Remedies Pvt. Ltd., Village Ogli, Kala Amb, and Tehsil: Nahan, District- Sirmour, Himachal Pradesh-173030, INDIA, are holding valid Drug Manufacturing License Nos. MNB/06/434 & MB/06/435 granted on 13.11.2006 & valid up-to 12.11.2026 and they are Market Standing for more than last three financial years. This certificate is issued at the request of the firm for the limited purpose of participating for Registration submitting the tenders in Government Institutions.

1.	Amitriptyline 10mg Tablet
2.	Gabapentine 100mg Tablet
3.	Levetiracetam 100 mg Injection D 28 0 050
4	Levetiracetam 500mg Table
5.	Naproxen 250mg Tablet D 2 80057 D 20 8 057
6.	Naproxen 500mg Tablet
7.	Sodium Valproate Injection 100 mg
8.	Aceclofenac 100 mg and Paracetamol 325 mg Tablet
9.	Metformin SR 500mg Tablet
10.	Thiamine 100 mg Injection

11	Methyl Prednisolone Sod. Succinnate 40 Mg Injection
12.	Ceftriaxone + Sulbactum 1.5gm Injection
13.	Cefuroxime 1.5gm Injection
14.	Atorvastatin 40 mg Tablet
14.	D10046
15.	Betahistine 16mg Tablet
16.	Cefuroxime 500 mg Tablet
17	Ondansetron 4mg Tablet
18.	TARIA (OTARIA)
	Dopamine Hydrochloride 40mg Injection
19.	Cefixime 100mg Tablet
20.	Paracetamol 650 mg Tablet
CPY	Sodium Valproate 500 mg Tablet
2	Pantoprazole 40mg And Domperidone 30mg Capsule
3.	Muprocin 2% w/w Ointment (GARIMA SHARMA)

Disti Solan

29 MAR 2025

Page 1 of 2

No. HFW-H (Drug) 288/176-HEALTH AND FAMILY WELFARE DEPARTMENT HIMACHAL PRADESH

Market Standing Cerificate

This is to certify that M/s Systole Remedies Pvt. Ltd., Village Ogli, Trilokpur road Kala Amb, Tehsil: Nahan, District- Sirmour, Himachal Pradesh-173030, INDIA, are holding valid Drug Manufacturing Licence Nos.NL-MNB/06/434&MB/06/435 granted on 13.11.2021& valid up-to 12.11.2026 and they are Market Standing for more than last three

Sr. No.	Generic name	years. Composition	94/000000000000000000000000000000000000	
08.	Pantoprazole Tablets	Each film coated tablet contains: Pantoprazole Sodium Eq. to Pantoprazole Excipients	IP	
09.	Pregabalin 75 SR + Methylcobalamin 1500mcg	Each uncoated bilayered tablet con Pregabalin (in Sustained Release form) Methylcobalamin	IP IP	75 mg 1500 mcg
10.	CefpodoximeProxetil Oral Suspension 100 mg/5ml	Each 5 ml contains: CefpodoximeProxetil Eq. to Cefpodoxime Excipients	.s IP	100 mg
11./	Meropenam Injection IP 250mg > ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○	Each Vial contains: Meropenam	IP	q.s 250 mg
12.	Linezolide Tablets 600 mg	Each uncoated tablet contains: Linezolid Excipients	IP 6	600 mg q.s
13.	Vancomycin Hydrochloride for injection IP	Each Vial contains: Vancomycin Hydrochloride (sterile) Eq. to Vancomycin		00 mg



haring og. 2023

Himachal Place ade4hp@gmail.com



29 MAR 2025

Attested to

Notary, PANCHKULA (Haryana)

Annexure-I

HFW-H (Drugs) 288/06 HEALTH AND FAMILY WELFARE DEPARTMENT HIMACHAL PRADESH

MARKET STANDING CERTIFICATE

This is to certify that M/s Systole Remedies Pvt. Ltd., Village Ogli, Kala Amb, and Tehsil: Nahan, District- Sirmour, Himachal Pradesh-173030, INDIA, are holding valid Drug Manufacturing License Nos. MNB/06/434 & MB/06/435 granted on 13.11.2006 & valid up-to 12.11.2026 and they are Market Standing for three financial years. This certificate is issued at the request of the firm for the limited purpose of participating for Registration submitting the tenders in Government Institutions.

		- 0	-			
L	SI	OI	r	rod	uc	IS:

Hydrocortisone Sodium Succinate for Injection IP 100mg For IM/IV USE 1 Itraconazole Capsules 100mg 1 Labetalol 100mg Tablets IP 1 Labetalol Hydrochloride 5mg, Methyl Paraben (As preservative) & Propyl Paraben Injection 1 Lactulose 10% Solution USP 1 Lactulose 10% Solution USP 2 Lactulose 10% Solution USP 3 Levocetirizine 5mg & Montelukast 10mg Tablets Meropenem 500mg Injection IP 3 Meropenem 1000mg Injection IP 3 Methylprednisolone Acetate 40mg Injection IP Methylprednisolone Sodium Succinate 1000mg Injection USP 3 Moxifloxacin 0.5% Ophthalmic Solution 3 Naproxen Tablets IP 500mg 4 Noradrenaline Bitartrate 2mg-1mg Injection IP 4 Ofloxacin Tablets IP 200 mg 4 Pantoprazole for Injection BP 40mg For IM/IV use 4 Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4 Piperacillin 1000mg & Tazobactam 125mg For Injection IP 4 Piperacillin 1000mg & Tazobactam 125mg For Injection IP 4 Piperacillin 4000mg & Tazobactam 125mg For Injection IP 4 Triamine Hydrochloride 100mg Injection IP 4 Triamine Hydrochloride 100mg Injection IP 4 Triancamic 500mg Injection IP (5ml) (For IV use) 4 Tranexamic 500mg Injection IP (5ml) (For IV use) 5 Ursodeoxycholic Acid 150mg Tablets IP	Sr. N	lo. Products Name
Itraconazole Capsules 100mg Labetalol 100mg Tablets IP Labetalol Hydrochloride 5mg, Methyl Paraben (As preservative) & Propyl Paraben Injection Lactulose 10% Solution USP Levocetirizine 5mg & Montelukast 10mg Tablets Meropenem 500mg Injection IP Meropenem 1000mg Injection IP Methylprednisolone Acetate 40mg Injection IP Methylprednisolone Sodium Succinate 1000mg Injection USP Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Attestod 15 and	28	Hydrocortisone Sodium Succinate for Injection IP 100mg For IM/IV LISE
Lactulose 10% Solution USP Levocetirizine 5mg & Montelukast 10mg Tablets Meropenem 500mg Injection IP Meropenem 1000mg Injection IP Methylprednisolone Acetate 40mg Injection IP Methylprednisolone Sodium Succinate 1000mg Injection USP Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP Attestody Timelol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	29	Itraconazole Capsules 100mg
Levocetirizine 5mg & Montelukast 10mg Tablets Levocetirizine 5mg & Montelukast 10mg Tablets Meropenem 500mg Injection IP Methylprednisolone Acetate 40mg Injection IP Methylprednisolone Sodium Succinate 1000mg Injection USP Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP Attestod to Ballets IP 500mg Tinamine Hydrochloride 100mg Injection IP Tranexamic 500mg Injection Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	30	Labetalol 100mg Tablets IP
Levocetirizine 5mg & Montelukast 10mg Tablets Levocetirizine 5mg & Montelukast 10mg Tablets Meropenem 500mg Injection IP Methylprednisolone Acetate 40mg Injection IP Methylprednisolone Sodium Succinate 1000mg Injection USP Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	31	Labetalol Hydrochloride 5mg, Methyl Paraben (As preservative) & Propyl Paraben Injection
Meropenem 500mg Injection IP Meropenem 1000mg Injection IP Methylprednisolone Acetate 40mg Injection IP Methylprednisolone Sodium Succinate 1000mg Injection USP Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	32	Lactulose 10% Solution USP
Meropenem 500mg Injection IP Methylprednisolone Acetate 40mg Injection IP Methylprednisolone Sodium Succinate 1000mg Injection USP Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	33	Levocetirizine 5mg & Montelukast 10mg Tablets
Methylprednisolone Acetate 40mg Injection IP Methylprednisolone Sodium Succinate 1000mg Injection USP Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	34	
Methylprednisolone Sodium Succinate 1000mg Injection USP Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	35	Meropenem 1000mg Injection IP
Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	36	Methylprednisolone Acetate 40mg Injection IP
Moxifloxacin 0.5% Ophthalmic Solution Naproxen Tablets IP 500mg Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	37	
Noradrenaline Bitartrate 2mg-1mg Injection IP Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	38	
Ofloxacin Tablets IP 200 mg Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	39	Naproxen Tablets IP 500mg
Pantoprazole for Injection BP 40mg For IM/IV use Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	40	Noradrenaline Bitartrate 2mg-1mg Injection IP
Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use Piperacillin 1000mg & Tazobactam 125mg For Injection IP Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	41	Ofloxacin Tablets IP 200 mg
Piperacillin 1000mg & Tazobactam 125mg For Injection IP Attested to Fig. 1 Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	42	Pantoprazole for Injection BP 40mg For IM/IV use
Piperacillin 1000mg & Tazobactam 125mg For Injection IP Attested to Fig. 1 Thiamine Hydrochloride 100mg Injection IP Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	43	Piperacillin 4000mg & Tazobactam 500mg For Injection IP 4.5 gm For IM/IV use
Tigecycline 50mg Injection Timolol Maleate 0.5% Eye Drops IP Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	44	Piperacillin 1000mg & Tazobactam 125mg For Injection IP
Timolol Maleate 0.5% Eye Drops IP Wotary, FAJICHKULA (III) Tranexamic 500mg Injection IP (5ml) (For IV use) Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP	45	
49 Tranexamic Acid Tablets IP 500 MG 50 Ursodeoxycholic Acid 150mg Tablets IP **Profile 1 (Smr) (For TV use) **Profile 1 (Smr) **Profile 1 (Smr) **Profile 1 (Smr) **Profile 2 (Smr) **Profile 2 (Smr) **Profile 2 (Smr) **Profile 3 (Sm	46	
49 Tranexamic Acid Tablets IP 500 MG 50 Ursodeoxycholic Acid 150mg Tablets IP **Profile 1 (Smr) (For TV use) **Profile 2 (1800) **Profile 2 (1800) **Profile 2 (1800) **Profile 3 (1	47	Timolol Maleate 0.5% Eye Drops IP
Tranexamic Acid Tablets IP 500 MG Ursodeoxycholic Acid 150mg Tablets IP * Programma 1800mg * Programma 1800mg	48	Tranexamic 500mg Injection IP (5ml) (For IV use)
Fidad, no. 45833	49	
51 Vildaglintin 50mg Tobleto	50	Ursodeoxycholic Acid 150mg Tablets IP
or inagripuit soing rapiets	51	Vildagliptin 50mg Tablets
52 Carboxymethylcethyldsic Eyo Drops IP 1%	52	Carboxymethylcellulosic Eyo Drops IP 1%

(GARIMA SHARMA) Asstt. Drugs Controller, cum-Licensing Authority HQ. Baddi, Distt. Solan Page 2 of 2 Himachal Pradesh

Annexure-I

HFW-H (Drugs) 288/06 HEALTH AND FAMILY WELFARE DEPARTMENT HIMACHAL PRADESH

MARKET STANDING CERTIFICATE

This is to certify that M/s Systole Remedies Pvt. Ltd., Village Ogli, Kala Amb, and Tehsil: Nahan, District- Sirmour, Himachal Pradesh-173030, INDIA, are holding valid Drug Manufacturing License Nos. MNB/06/434 & MB/06/435 granted on 13.11.2006 & valid up-to 12.11.2026 and they are Market Standing for three financial years. This certificate is issued at the request of the firm for the limited purpose of participating for Registration submitting the tenders in Government Institutions. List of Products:

1	Acyclovir Tablets IP 400 mg
2	Amikacin Sulphate 100mg Injection IP (2ml) (For IM/IV use)
3	Amikacin Sulphate 500mg Injection IP (2ml) (For IM/IV use)
4	Artesunate for Injection IP 60mg For IM/IV USE
5	Atorvastatin Tablets 10mg
6	Atorvastatin Tablets 40mg
7	Azithromycin 100mg Oral Suspension IP
8	Azithromycin 200mg Oral Suspension IP
9	Azithromycin 250mg Tablets IP
10	Azithromycin 500mg Tablets IP
11	Cefixime Tablets IP 200mg
12	Cefixime Oral Suspension IP 50 mg/5ml
13	Cefotaxime Sodium 1000mg Injection IP
14	Ceftazidime For Injection IP 1000 mg For IM/IV use
15	Ceftriaxone 1000mg Injection IP For IM/IV use
16	Ceftriaxone 500mg Injection IP For IM/IV use Attested Copy
17	Cefuroxime Axetil 500mg Tablets IP
18	Clarithromycin 500mg Injection Notary PANCHKULA (Haryana)
19	Diclofenac Sodium Injection IP 75 mg/ml For IM use only
20	Dopamine Hydrochloride 40mg Injection IP
21	Doxycycline 100mg Cancular ID
22	Febuxostat 40mg Tablets \$26,0003
23	Fexofenadine Hydrochloride 120mg Tablets I.P.
24	Flucoritizate 150mg Tablets IP
25	Gentamicin lagection IP 40mg/ml (Vet.) For IM/IV use
26	Glimepiride Ing & Metformin HCl (Prolonged Released) 500mg Table BARIMA SHARMA)
27	Gimepiride Tablets IP 1mg Asstt. Durgs Controller

Himachal Pradesh





No. HFW-H (DRUGS)-288/06 Health & Family Welfare Department Baddi , Himachal Pradesh

PRODUCTION CAPACITY CERTIFICATE PER DAY PER SHIFT OF 60 DAYS

Ref No.:

Date:

Name and Address of the Manufacturer :

SYSTOLE REMEDIES PVT LTD

(Factory Address to be indicated)

Vill. Ogli Kala Amb Tehsil Nahan,

Sirmour (H.P.)173030

Particulars of the License number

MNB/06/434& MB/06/435

Installed Capacity particulars

Tablets, Capsules, Dry Syrup, Liquid Injections & Dry Injection (Amp & Vial),

Liquids, Syrup, Ointment, Ophthalmic

S.No.	Section & Dosage Forms	Capacity Per Day Per Shift Qty. in Number of unit	Per Day / Shift 09:00 to 5: 30	Total Capacity of 60Days / shift Qtv. in No. of units
	Tablets & Capsules (General Blocks)	6.0 Lac Tabs/Caps	One General	3.6 Crore Tabs/Caps
	Tablets & Capsules (Betalactam Blocks)	2 Lac Tabs/Caps	One General	1.2 Crore Tabs/Caps
	Liquid Injection (Ampoule)	50000 Vials	One General	
	Liquid Injection (Vials)	30000 Vials		30 Lac Ampoules
	Dry Injection (Vials)	80000 Vials	One General	18 Lac Vials
	Dry Syrups		One General	48 Lac Vials
	Liquid Syrup	10000 Bottle	One General	6 Lac Bottles
		20000 Bottle	One General	12 lac Boule
	Oistment	10000 Tube	One General	6 Lac Tube
	Ophthalmic	15000 Nos	One General	9 Lac nos

This Certificate is issued on the request on the request of the firm for participation in various tenders enquires floated by various Govt. amd Semi-Government institutions and Hospitals from time to time.

> Craims oy. 2023 (GARIMA SHARMA) Asstt. Drugs Controller, (Gardoumshipana)-3 Authority MastHQ:Beacouted legolan

-eamHimachial Prodbshity, O/o State Drugs Controller,

H.P., Baddi Distt. Solan-173 205,

\$1795-231288, sdc4hp@gmail.com

'B SINCH WOHRULA (Haryana)

CamScanne



KBB & CO

Chartered Accountants

Format-VI

AVERAGE ANNUAL TURNOVER CERTIFICATE

To,

Managing Director, UPMSCL Ltd.

SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension,

Lucknow, Uttar Pradesh-226010

We hereby certify that <u>M/S Systole Remedies Pvt. Ltd.</u> (the name of the participant in the tender) who is participating in the tender for Supply of Drugs, called by UPMSCL Ltd. Lucknow, vide Tender reference number UPMSCL/Drugs-223/25, Date: 27.03.2025 has a pharmaceutical manufacturing/Sales turnover given as below: -

Turnover in the year of 2021-22

RS.

10,55,49,855/-

Turnover in the year of 2022-23

RS.

38,49,44,880/-

Turnover in the year of 2023-24

RS.

46,59,29,417/-

The above information is correct and true.

Office seal

Signature

Name of Proprietor / Partner/Authorized Signatory of bidder with firm's rubber stamp/seal

CERTIFIED BY CHARTERED ACCOUNTANT (CA)

Name of Chartered Accountant (In capital letters): CA SAHIR BHASIN

Regd. No. of Chartered Accountant: 516324

NOTE: The turnover of other than participants will not be accepted. Audited balance sheet & profit & loss statement for last three years (Self-attested & Certified by Cash all also been closed as proof of the claim). In case the audited balance sheet for recent last completed financial year (2024-25) is not ready provisional balance sheet shall be acceptable.

SYSTOLE REMEDIES PRIVATE LIMITED

Balance Sheet as at 31st March 2022

Rs in thousands.

***************************************	Particulars	Note No.	As At March 31, 2022	As At March 31, 2021
A	EQUITY AND LIABILITIES	NO ₄	·····	
1	Shareholders' funds			
	(a) Share capital		17 000 00	15,000.00
	(b) Reserves and surplus	3	15,000.00	
	(c) Money received against share Warrants	4	23,718.66	22,164.04
	- Hamist strate Available			*
			38,718.66	37,164.04
2	Share application money pending allotment			
3	Non-current liabilities			
	(a) Long term borrowings			
	(b) Deferred - 18 controllings	5	26,341.92	25,825.95
	(b) Deferred tax liabilities (net)	25.4	103.10	306.12
	(d) Long term liabilities			
	(d) Long-term provisions			
4	Current liabilities		26,445.02	26,132.07
	(a) Short term borrowings			
	(b) Trade payables	6	504.06	
-	(c) Other current liabilities	7	90,947.34	19,505.29
***************************************	(d) Short-term provisions	8	4,932.34	603.07
	1-1 State term provisions	9		1,520.16
			96,383.74	21,628.52
	TOTAL			
	ASSETS		1,61,547.42	84,924.63
1	Non-current assets			
	(a) Property, Plant, Equipment & Intangible assets			
	Property Plant and Equipment			
	intangible assets	10	30,806.86	25,490.80
	(b) Non-current investments			•
1	(c) Deferred tax assets (net)		•	•
	(d) Long-term loans and advances	*	*	•
	(c) Other non-current assets	11	565.18	553.57
				•
	urrent assets		31,372.04	26,044.37
1	a) Current investments			
	b) Inventories	12		•
- 1	c) Trade receivables	13	83,472.89	43,793.74
(d) Cash and cash equivalents	14	33,571.09	11,943.58
- 11	e) Short term loans and advances	15	2,875.40	861.52
1.0	1) Other current assets	16	10,183.77	250.11
oli in general		10	72.23	2,031.31
			1,30,175.38	58,880.26
	TOTAL	-	1,61,547.42	
26	e accompanying notes to the Financial Statements.			84,924.63

in terms of our report of even date attached.

For KBB & CO Chartered Accountints.

CA Saint Bhasin

Mem No 518324 Partner

Date: 28th September 2022

Place : Panchkula | UDIN 22516324BEANRRB406

Systole Remain on behalf of Board of Directors

Unector Rovneet Singh (DIN

08445822)

Director

Payneet Singh Kalra (DIN 09239772)

Director

es PVL Ltd

Attested to To True

Notary, FANGHKULA (Haryana)



29 MAR 2025

SYSTOLE REMEDIES PRIVATE LIMITED

Statement of Profit and Loss for th

	Note	For the year ended	For the year ender
CONTINUING COST	No.	31st March 2022	31st March 2021
Revenue from			
Other locary	17	1.05 540 96	35 007 6
A THE MICHIGAN			25,057.6
Yestak lana	10	17.31	1.4
(1+2)			
E		1,05,562.77	25,059.0
list Cost of Material Consumed	10	1 20 020	
(c) Commission of stock in trade	19	1,29,933.13	18,979.53
cranges in inventories of finished goods, work-in-	20		•
TO THE BOOK STORES THE PROPERTY OF THE PROPERT	20	(39,679.15)	(3,077.99
(a) Employee benefits expense	71		
(V) Finance costs			2,645.74
(a) Depreciation and amortization expense			2,244.56
int Other expenses	100000000000000000000000000000000000000		1,459.27
Profit / thanks	" r		3,852.05
and tax (2 a)	-		25,104.16
12.41		1,331.00	(1,045.08)
Exceptionality			
Profit / then the t			
(6 ± 6)	-	1 351 60	(1.045.00)
		1,551.00	(1,045.08)
Profit / floor) but			
(3±4)		1.351.60	(1,045.08)
Jaconnes / they are			12,0-3.001
(a) Current tax expenses		900	
(b) (Loss): Max conduction to the content year			
ic) Income Tax of account (where applicable)			
(c) Short / [Excess according to			8.39
relating to prior yrs.		•	
id) Deferred tox			
	25.4	(203.02)	28.79
w. ov. exherise \ (ocuent)		(203.02)	37.18
rolit / (Loss) from continues			
(1-23) Hom continuing operations (9 - 10)		1,554.62	(1,082.26)
DISCONTINUING OPERATIONS			
Profit / (Loss) from discontinuing angentian			Observation
the state of the s			
OTAL OPERATIONS			
[20, 10, 74]		1,554.62	(1,082.26)
arnings per share (p. Ks. 10/- each).			
a) Basic (in As.)			000000000000000000000000000000000000000
J Dilated (in Rs.)		1.04	(0.72)
		104	
e accompanying notes to the financial statements.		1.04	(0.72)
	CONTINUING OPERATIONS Revenue from operations Other Income Total Income (1+2) Expenses (a) Cost of Material Consumed (b) Purchases of stock in trade (c) Changes in inventories of finished goods, work-in- progress and stock-in-trade (d) Employee benefits expense (e) Finance costs (f) Depreciation and amortization expense (g) Other expenses Total expenses (1+2) Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4) Exceptional items Profit / (Loss) before extraordinary items and tax (5 ± 6) Extraordinary items Profit / (Loss) before tax (3 ± 4) Tax expense / (benefit): (a) Current tax expense for current year (b) (Less): MAT credit (where applicable) (c) Income Tax of previous years (c) Short / (Excess) provision for tax relating to prior yrs. (d) Deferred tax (et tax expense / (benefit) Profit / (Loss) from continuing operations (9 - 10) DISCONTINUING OPERATIONS Profit / (Loss) from discontinuing operations OFAL OPERATIONS Profit / (Loss) for the year (11 + 12) Amolings per share (or Rs. 10/- each): (a) Basic (in Rs.)	CONTINUING OPERATIONS Revenue from operations Other income 18 Total income (1+2) Expenses 1a) Cost of Material Consumed 1b) Purchases of stock in trade (c) Changes in inventories of finished goods, work-in- progress and stock-in-trade (d) Employee benefits expense (e) Finance costs (f) Depreciation and amortization expense (g) Other expenses 1atal expenses (1+2) Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4) Exceptional items Profit / (Loss) before extraordinary items and tax (5 ± 6) Extraordinary items Profit / (Loss) before tax (3 ± 4) Tax expense / (benefit): (a) Current tax expense for current year (b) (Less): MAT credit (where applicable) (c) Income Tax of previous years (c) Short / (Excess) provision for tax relating to prior yrs. (d) Deferred tax (et tax expense / (benefit) Profit / (Loss) from continuing operations (9 - 10) DISCONTINUING OPERATIONS Profit / (Loss) from discontinuing operations OTAL OPERATIONS Profit / (Loss) for the year (11 + 12) Aminings per share (ox 8x. 10/- each): (a) Basic (in Rs.)	CONTINUING OPERATIONS Revenue from operations Other Income Other Income 17 1,05,549.86 18 17.91 Total Income (1+2) Expenses 19 1,05,562.77 Expenses 19 1,29,933.13 19 1,29,933.13 20 (39,679.15) 21 1,29,933.13 22 (39,679.15) 23 progress and stock in trade 24 Employee benefits expense 25 Employee benefits expense 26 Finance costs 27 416.76 28 925.75 29 17,041.75 29 17,042.71.75 20 1,042.71.75 20 1,042.71.75 21 1,351.60 Extraordinary items 29 1,351.60 Extraordinary items 20 1,351.60 Extraordinary items 21 2,042.71.17 1,351.60 Extraordinary items 21 3,551.60 Extraordinary items 22 416.76 1,351.60 Extraordinary items 23 1,351.60 Extraordinary items 24 (203.02) Extraordinary items 25 4 (203.02) Extraordinary items 26 (Less): MAT credit (where applicable) 27 (Less): MAT credit (where applicable) 28 (1,100 income Tax of previous years 29 1,351.60 Extraordinary items 20 1,351.60 Extraordinary items 21 2,042.71.17 1,351.60 Extraordinary i

Systoli For and on behalf of Board of Brectors

For KBb & CO Charteget Accounts

CA Safair Ahasia Mem No 516324

Partne; Date: 28th September 2022

Place : F alikula | UDIN 22516324BEANRRB406

Rovneet Singh (DIN 08445822) Olrector

Pavneet Singh Kalra (DIN 09239772)

Director

Attested to Be True Copy

Notary,



29 MAR 2025

Remedie

288

SYSTOLE REMEDIES PRIVATE LIMITED

Balance Sheet as at 31st March 2023

A 1	FOURT	No.	2023	As At March 31,
	EQUITY AND LIABILITIES		2020	2022
*	Shareholders' funds			
	(a) Share capital	3		
	(b) Reserves and surplus		15,000.00	15,000.0
	(c) Money received against share Warrants	4	26,886.30	23,718.6
			41,886.30	38,718.6
2	Share application money pending allotment			
3	Non-current liabilities			
	(a) Long term borrowings			
	(b) Deferred tax liabilities (net)	5	25,941.92	26,341.9
	(c) Other long term liabilities	25.4	630.57	103.1
	(d) Long-term provisions	-		
	(e) zong term provisions			
4	Current liabilities	_	26,572.49	26,445.0
	(a) Short term borrowings	6		
	(b) Trade payables	7	28,619.31	504.06
	(c) Other current liabilities		116,433.72	90,947.34
	(d) Short-term provisions	8	7,859.95	4,932.34
		9	785.05	
			153,698.03	96,383.74
	TOTAL		222,156.82	1/4
	ASSETS			161,547.44
	Non-current assets			
	(a) Property, Plant, Equipment & Intangible assets			
	Property Plant and Equipment	10	42,798.57	30,000,00
	Intangible assets	10	,,,-,	30,806.86
	(b) Non-current investments	-		
	c) Deferred tax assets (net)			*
	d) Long-term loans and advances	11	576.66	•
- 1	(e) Other non-current assets		370.00	565.18
2 0	urrent assets	dies	43,375.23	31,372.04
	a) Current investments	13/		
	b) Inventories	NA I		•
	c) Trade receivables	£ 12.	88,001.39	83,472.89
		13	83,430.08	33,571.09
	d) Cash and cash equivalents e) Short term loans and advances	Signa 14	1,477.35	2,875.42
	f) Other current assets	15	5,675.97	10,139.46
,	other current assets	16	196.80	116.54
			178,781.59	130,175.40
	TOTAL		222,156.82	161 647 44
Se	e accompanying notes to the Financial Statements.			161,547.44
erms o	f our report of even date attached.	RARY		*
KBB 8	Accountants	Participal	12 11	f Board of Directors
	hasin PRM *	COVT OF		
ahir B n No 5	16324			avneet Singh Kalra
n No 5		d to Bestine Co	(DIN 08445853) Director	(DIN 09239772) Director

Notary PANCHIQUEA (Haryana)



SYSTOLE REMEDIES PRIVATE LIMITED

Statement of Profit and Loss for the year ended 31st March 2023 Rs in thousands. For the year ended For the year ended **Particulars** 31st March 2023 31st March 2022 No. CONTINUING OPERATIONS Revenue from operations 1 17 384,944.88 105,549.86 Other income 2 18 1,182.39 12.91 Total income (1+2) 386,127.27 105,562.77 4 Expenses (a) Cost of Material Consumed 19 339,790.40 129,933.13 (b) Purchases of stock in trade (c) Changes in inventories of finished goods, work-in-progress (4,528.50)(39,679.15)and stock-in-trade (d) Employee benefits expense 21 19,454.49 5,572.93 (e) Finance costs 22 1,859.14 358.63 (f) Depreciation and amortization expense 23 2,276.42 925.75 (g) Other expenses 24 22,795.18 7,099.86 Total expenses (1+2) 381,647.13 104,211.15 Profit / (Loss) before exceptional and extraordinary items and 4,480.14 1,351.62 tax (3 - 4) Exceptional items Profit / (Loss) before extraordinary items and tax (5 ± 6) 4,480.14 1,351.62 Extraordinary items 8 Profit / (Loss) before tax (3 ± 4) 4,480.14 1,351.62 10 Tax expense / (benefit): (a) Current tax expense for current year 785.05 (b) (Less): MAT credit (where applicable) (c) Income Tax of previous years (c) Short / (Excess) provision for tax relating to prior yrs. (d) Deferred tax 25.4 527.47 (203.02)Net tax expense / (benefit) 1,312.52 (203.02)11 Profit / (Loss) from continuing operations (9 - 10) 3,167.62 1,554.64 DISCONTINUING OPERATIONS Profit / (Loss) from discontinuing operations 12 Remedies TOTAL OPERATIONS 13 Profit / (Loss) for the year (11 + 12) 3,167.62 1,554.64 14 Earnings per share (of Rs. 10/- each): (a) Basic (in Rs.) 2.11 1.04 (b) Diluted (in Rs.) 2.11 1.04 See accompanying notes to the financial statements.

In terms of our report attached.

For KBB & CO Chartered Accountants

CA Sahir Bhasin Mem No 516324 Partner

Date: 26.08.2023

Place: Panchkula | UDIN 23516324BGVTAE7813

Harsimran Singh (DIN 08445853)

Director

Pavneet Singh Kalra (OIN 09239772)

For and on behalf of Board of Directors

Director



Systole Remedies Private Limited

Balance Sheet as at 31st March 2024

Rs in thousands. **Particulars** Note As At March 31, As At March 31. No. **EQUITY AND LIABILITIES** 2024 2023 Shareholders' funds (a) Share capital 3 (b) Reserves and surplus 15,000.00 15,000.00 (c) Money received against share Warrants 4 30,853.63 26,886.32 45,853.63 41,886.32 2 Share application money pending allotment Non-current liabilities (a) Long term borrowings 5 (b) Deferred tax liabilities (net) 25,941.92 25,941.92 6 (c) Other long term liabilities 1,789.76 630.57 (d) Long-term provisions 27,731.68 Current liabilities 26,572.49 (a) Short term borrowings 7 54,902.49 (b) Trade payables 28,619.31 8 1,08,696.60 (c) Other current liabilities 1,16,433.72 9 11,203.80 (d) Short-term provisions 7,859.95 10 397.63 785.05 1,75,200.52 1,53,698.03 TOTAL 2,48,785.83 2,22,156.84 **ASSETS** Non-current assets (a) Property, Plant, Equipment & Intangible assets Property Plant and Equipment 11 72,730.98 42,798.57 Intangible assets (b) Non-current investments (c) Deferred tax assets (net) (d) Long-term loans and advances 12 1,040.99 (e) Other non-current assets 576.66 73,771.97 2 Current assets 43,375.23 (a) Current investments (b) Inventories 13 48,291.34 88,001.39 (c) Trade receivables

Remedies Purising Signature

See accompanying notes to the Financial Statements. In terms of our report of even date attached.

(d) Cash and cash equivalents

(f) Other current assets

(e) Short term loans and advances

For KBB and CO

Chartered Accountants

FRN 023819N

FRN 023819N

TOTAL

CA Ankush Goyal Mem No: 556307

Partner

Dated: 22nd Aug 2024

Place: Panchkula | UDIN: 24556307BKETWR9434

For and on behalf of Board of Directors

For Systole Remedies Pvt_Ltd.

14

15

16

For Systole Remedies Pvt. Ltd.

83,430.08

1,477.37

5,872.77

1,78,781.61

2,22,156.8

Director

1,11,247.11

15,429.67

1,75,013.86

2,48,785.83

45.74

Director

Ravneet Singh.

Director

Pavneet Singh Katra

Director

Attested to Be Jun Co

9 MAR 2025 NAIB SINGIA (Haryana)

Systole Remedies Private Limited

Rs in thousands.

tement of Profit and Loss for the year ended 31st Mar	ch 202	4	Rs in thousands.
	Note	For the year ended	For the year ended
Particulars		31st March 2024	31st March 2023
A CONTINUING OPERATIONS	17	4 65 020 42	3,84,944.88
Revenue from operations	17	4,65,929.42	
Other income	18	565.06	1,182.39
Total income (1+2)		4,66,494.48	3,86,127.27
Expenses			
(a) Cost of Material Consumed	19	3,59,281.86	3,39,790.40
(b) Purchases of stock in trade	-	•	*
(c) Changes in inventories of finished goods/work-in-progress/st	20	39,710.05	(4,528.50)
(d) Employee benefits expense	21	29,898.72	19,454.49
(e) Finance costs	22	5,261.41	1,859.14
(f) Depreciation and amortization expense	23	2,396.40	2,276.42
(g) Other expenses	24	24,421.91	22,795.18
Total expenses (1+2)		4,60,970.35	3,81,647.13
Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		5,524.13	4,480.14
5 Exceptional items		-	
Profit / (Loss) before extraordinary items and tax (5 + 6)		5,524.13	4,480.14
B Extraordinary items		•	•
Profit / (Loss) before tax (3 + 4)		5,524.13	4,480.14
0 Tax expense / (benefit):			
(a) Current tax expense for current year	25	397.63	785.05
(b) (Less): MAT credit (where applicable)			
(c) Short / (Excess) provision for tax relating to prior yrs.			
(d) Deferred tax	26	1,159.19	527.46
Net tax expense / (benefit)		1,556.82	1,312.51
Profit / (Loss) from continuing operations (9 - 10)		3,967.31	3,167.63
11 DISCONTINUING OPERATIONS			
12 Profit / (Loss) from discontinuing operations		•	-
C TOTAL OPERATIONS			
13 Profit / (Loss) for the year (11 + 12)		3,967.31	3,167.63
14 Earnings per share:			
(a) Basic (in Rs.)		2.64	2.11
(b) Diluted (in Rs.)		2.64	
See accompanying notes to the financial statements.			
In terms of our report of even date attached.			V

In terms of our report of even date attached.

For KBB and CO

Chartered Accountants

FRN 023819N

CA Ankush Goyal Mem No: 556307

Partner

Dated: 22nd Aug 2024

Place: Panchkula | UDIN: 24556307BKETWR9434

For and on behalf of Board of Directors

For Systole Remedies Pvt. Ltd. For Systole Remedies Pvt. Ltd.

Director

Ravneet Singh.

Pavneet Singh Kalra

Director

Director

Director

Bond



Indian-Non Judicial Stamp Haryana Government



Date: 24/12/2024

Certificate No.

P0X2024L82

GRN No.

125621085



Deponent

Stamp Duty Paid: ₹ 101

(Rs. Only)

Penalty:

₹0

(Rs. Zero Only)

Name :

Systole Remedies Pvtltd

H.No/Floor: Na

City/Village: Village ogli

Na

Sector/Ward: Na

District : Sirmour

Landmark: Na

State: Himachalpradesh

Phone:

70*****56

Purpose: FOR TENDER PURPOSE OF SYSTOLE REMEDIES to be submitted at Panchkula

The authenticity of this document can be verified by scanning this QrCode Through smart phone or on the website https://egrachry.nic.i

FORMAT-VII

'NotarizedonRs.100/-NonJudicialstamp paper' <u>DECLARATION</u>



I, RAVNEET SINGH S/O JITENDER SINGH R/O #267, SECTOR 26 PANCHKULA-134116 HARYANA do solemnly affirm:

That my Firm/Company/Corporation/LLP is participating in tender noUPMSCL/Drugs-223/25 DT.14/NOV/2025 of

MD,Uttar PradeshMedical Supplies Corporation Ltd., Lucknow and I am executingthis declarationfor myself and on behalf of my Firm/Company/Corporation/LLP.

That my Firm/Company/Corporation/LLP and it's Proprietor or any of its Directors/Partners/Authorised signatories has not been convicted under the provisions of Drugs and Cosmetics Act and Rules there under, Drug (Prices Control) Order or any other law related to drugs by any Court of India. I shall inform the UPMSCL immediately, if there is any conviction from aforesaid any authority.

That my Firm/Company/Corporation/LLP is not under blacklisting/ debarring by anyTender Inviting Authority, UPMSCL for any reason or by Central Govt./any State Govt. or organizations/agencies there under on grounds of Drug Quality/Regulatory non-compliance issues.

In case of exemption of my Firm/Company/Corporation/LLP from payment of Earnest Money Deposit by a Governorder, I undertake to pay the said sum without any demur on receipt of demand issued by the Tender Inviting Authority.

That, the rates quoted are not higher than the rates quoted to other Government/Semi-Government/Autonomous/Public Sector Hospitals/ Institutions/ Organizations situated in India in the same mancial year and also not higher than the prices notified by National Pharmaceutical Pricing Authority under Drug (price control) order. In case my firm/company/Corporation/LLP decides to sell the same drugs at lower prices, to Central Govt. or any State Government or their organizations/agencies, the same will be

Page49of65



intimated to UPMSCL immediately and the contract shall be revised accordingly.

That the information given by me in this tender formistrue and correct to the best of myknowledge and belief and I am aware of the 'Tender Inviting Authority's' right to forfeit the Earnest Money Deposit and/or Security Deposit and blacklist my Firm/Company/Corporation/LLP, if any information furnished is provedfalse.

That I have read the terms and conditionsofthe tender and I andmyfirm/Company/Corporation/LLPagreeto abide by these terms and conditions and other guidelines issued in this regard.

DATE: Signature:

Name: RAVNEET SINGH Designation:Director

SEAL:

Note: Letter of Authorization to sign the tender document/related papers/deeds are to be enclosed with this undertaking.

I Identify the deponent/Executant Who has Signed /Thumb Marked

#1294, RC S EC 17 PKL. Adminer 50/8/1152 7377

Page50of65



🧿 Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

\$STIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

FORMAT-VIII MANUFACTURING/IMPORTEXPERIENCEDETAILOFQUOTEDDRUGS

NameoftheBidder/ Supplier:Systole remedies pvt. Ltd.

SI. No	Drugcode	DrugNamewith strength	No of batches&quantit y manufacturedin year 2021	No of batches &quantity manufacturedin the year	No of batches &quantity manufacturedinthe year 20
1	D100046	Atorvastatincalcium tabletIP40mg1*10strips	50batch (5cr. tab)	60 batch (6crore)	70batch (7crore)
2	D040089	CefuroximeaxetilTabletIP5 00mg 1*4strips	50batch (5cr. tab)	60 batch (6crore)	70batch (7crore)
3	D260003	Febuxostat40mgtab1*10stri	50batch (5cr. tab)	60 batch (6crore)	70batch (7crore)
4	D280050	Levecetram100mg/mlInjection5mlVial	20batch (8lac inj)	25batch (10lac inj)	30batch
5	D280057	Leveracetam tab500mg1*10strips	50batch (5cr. tab)	60 batch (6crore)	(12lac inj) 70batch (7crore)
	D040094	Meropenem250mginjdrypo wderwithwatercombi pack 1*1dry powderVial	20batch (8lac inj)	25batch	30batch
,	D160016	MethylprednisoloneInjectio n40mg/ml(1ml)1mlvial	20batch (8lac inj)	(10lac inj) 25batch	(12lac inj) 30batch
3	D020010	Pantaprazole40mg(tab)1*10 strip	50batch (5cr. tab)	(10lac inj) 60 batch (6crore)	(12lac inj) 70batch (7crore)

Notary)

29 MAR 2025

Page**51**of**67**



Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

9	Thiamineinjection100mg/m l,2mlVial	20batch	25batch	30batch
		(8lac inj)	(10lag inj)	(12lac inj)

SIGNATUREOFTHEAUTHORIZEDREPRESENTATIVE

NAME: RAVNEET SINGH

DESIGNATION DIRECTOR

NAMEOFTHEFIRM/BIDDER: SYSTOLE REMEDIES PVT. LTD.___

Thorised

STAMP OF THEFIRM/BIDDER



Notary, PANCHICULA (Haryana)
29 MAR 2025

Page52of67



O Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

FORMAT-IX

LISTOFGOVTORGANIZATIONSTOWHICHBIDDERISANEXISTING SUPPLIER

SI. No	Organization Name	No.of Item under Contract	Whetherblacklisted/Debarredforany drug.(Ifyes,Namesoftheitem)
1	ANDHRA PARDESH MEDICAL CORPORATION	5	NO
2	TELANGANA MEDICAL CORPORATION	8	NO
3	DDU HOSPITAL -DELHI	3	NO

SIGNATUREOFTHEAUTHORIZEDREPRESENTATIVE

NAME: RAVNEET SINGH

DESIGNATION DIRECTOR_____


NAMEOFTHEFIRM/BIDDER: SYSTOLE REMEDIES PVT. LTD.___

STAMP OF THEFIRM/BIDDER____

Attested as Identified

Notary, PANCHKULA (Haryana)





Government of India Form GST REG-06 [See Rule 10(1)]

Registration Certificate

Registration Number:02AAJCS3700R2Z6


*	Legal Name	SYSTOLE	SYSTOLE REMEDIES PRIVATE LIMITED			
2.	Trade Name, if any	SYSTOLE	SYSTOLE REMEDIES PRIVATE LIMITED			
3.	Constitution of Business	Private Lim	ited Company			
4.	Address of Principal Place o Business	f TEHSIL N	TEHSIL NAHAN, VILLAGE OGLI, KALA AMB, Moginand Industrial Area, Sirmaur, Himachal Pradesh, 173030			
5.	Date of Liability	01/07/2017				
6	Date of Validity	From	01/07/2017	To	Not Applicable	
7.	Type of Registration	Regular				
8.	Particulars of Approving Aut	hority Cent	re Goods and Service	es Tax Act, 201	7	
Signal	ure	Digitally 3 GOODS TAX NET	WHATOWN TOPPED TO US AND SERVICES WORKIA 220 23 / 3:30.24			
Name		ISHWAR DAS	3			
Desig	nation	Superintendent				
	ictional Office	Nahan Circle-J				
липад	**************************************					

This is a system generated digitally signed Registration Certificate issued based on the approval of application granted on 25/04/2022 by SYSTOLE PARENTS PUT the jurisdictional authority.

emedie

Notary, PAYICHKULA (Haryana)





GSTIN

02AAJCS3700R2Z6

Legal Name

SYSTOLE REMEDIES PRIVATE LIMITED

Trade Name, if any

SYSTOLE REMEDIES PRIVATE LIMITED

Total Number of Additional Places of Business(s) in the State

0



SYSTERENEDIES POR LITTOR

Ramadias Att. La.



Attested to Be Taya Copy

Notary, PANCHKULA (Haryana)



GSTIN

02AAJCS3700R2Z6

Legal Name

SYSTOLE REMEDIES PRIVATE LIMITED

Trade Name, if any

SYSTOLE REMEDIES PRIVATE LIMITED

Details of Managing / Whole-time Directors and Key Managerial Persons



Name

RAVNEET SINGH

Designation/Status

DIRECTOR

Resident of State

Rajasthan

Name

JITENDER MOHAN KALRA

Designation/Status

DIRECTOR

Resident of State

Rajasthan

Name

HARSIMRAN SINGH KALRA

Designation/Status

DIRECTOR

Resident of State

Name

Rajasthan

MANDEEP SINGH KALRA

Designation/Status

DIRECTOR

Resident of State

Rajasthan

Name

PAVNEET SINGH KALRA

Designation/Status

DIRECTOR

Resident of State

Rajasthan

Remedies

SYSTOLE REMEDIES PUT. LTD.

POWNEST OFFICTOR


Notary, PANCHAULA (Haryana)





भारत सरकार

Government of India





Ministry of Micro, Small and Medium Enterprises

UDYAM REGISTRATION CERTIFICATE

UDYAM REGISTRATION NUMBER

UDYAM-HP-10-0000933

NAME OF ENTERPRISE

M/S SYSTOLE REMEDIES PRIVATE LIMITED

TYPE OF ENTERPRISE *

SNo.	Classification Year	Enterprise Type	Classification Date
1	2023-24	Small	09/05/2023
2	2022-23	Micro	26/06/2022
3	2021-22	Micro	16/05/2021
4	2020-21	Small	13/03/2021

MAJOR ACTIVITY

MANUFACTURING

SOCIAL CATEGORY OF ENTREPRENEUR

GENERAL

NAME OF UNIT(S)

S.No.	Udyog Aadhaar Memorandum	Unit(s) Name
1	HP10B0001630	SYSTOLE REMEDIES PRIVATE LIMITED

OFFICAL ADDRESS OF ENTERPRISE

Flat/Door/Block No.	TRILOKPUR ROAD	Name of Premises/ Building	SYSTOLE REMEDIES PVT LTD
Village/Town	OGLI	Block	OPPOSITE PETROL PUMP
Road/Street/Lane	TRILOKPUR ROAD	City	KALA AMB
State	HIMACHAL PRADESH	District	SIRMAUR, Pin 173030
Mobile	8949549065	Email:	ravneetsinghkalra@gmail.com

DATE OF INCORPORATION / REGISTRATION OF ENTERPRISE

24/01/2005

DATE OF COMMENCEMENT OF PRODUCTION/BUSINESS

24/01/2005

NIC 5 Digit

20237 - Manufacture of cosmetics and tolleteries

(includes manufacture of pre-shave, shaving or after

shave preparations; personal deodorants and antirespirants; perfumed bath salts and other bath

preparations; beauty or make-up preparations and

preparations for the care of the skin, other than medicaments; manicure and pedicure preparations etc.)

			1000	1.
1	21 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	21001 - Manufacture of medicinal substances used in the manufacture of pharmaceuticals: anythogics, endocrinal products, basic vitamins; opinin derivatives; sulphardrugs; serums and plasmas; salicytic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.	ar.
2	21 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	21002 - Manufacture of allopathic pharmaceutical preparations	7
3	21 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	21003 - Manufacture of `ayurvedic' or `unani' pharmaceutical preparation	7.
4	21 - Manufacture of pharmaceuticals,	2100 - Manufacture of pharmaceuticals, medicinal	21005 - Manufacture of veterinary preparations	1

NIC 4 Digit

chemical and botanical

2023 - Manufacture of soap

and polishing preparations,

and detergents, cleaning

perfumes and toilet

preparations

products

NATIONAL INDUSTRY CLASSIFICATION CODE(S)

DATE OF UDYAM REGISTRATION

13/03/2021

* In case of graduation (upward/reverse) of status of an enterprise, the benefit of the Government Schemes will be availed as per the provisions of Notification No. S.O. 2119(E) dated 26.06.2020 issued by the M/o MSME.

Disclaimer: This is computer generated statement, no signature required. Printed from Paps and variety station gov. in & Date of printing: - 20/02/2024

For any assistance, you may contact:

1. District Industries Centre: KALAAMB (HIMACHAL PRADESH)

2. MSME-DFO:

SOLAN (HIMACHAL PRADESH)

SNo.

NIC 2 Digit


medicinal chemical and

botanical products

20 - Manufacture of

chemicals and chemical

Notary, PANO



Manufacturing

Manufacturing

Manufacturing

Manufacturing



भारत सरकार Government of India सूक्ष्म, लघु एवं मध्यम उद्यम मंत्रालय



Ministry of Micro, Small and Medium Enterprises

Udyam Registration Number : UDYAM-HP-10-0000933

Type of Enterprise	SMALL	Major Activity	Manufacturing
Type of Organisation	Private Limited Company	Name of Enterprise	M/S SYSTOLE REMEDIES PRIVATE LIMITED
Owner Name	M/S SYSTOLE REMEDIES PRIVATE LIMITED	PAN	AAJCS3700R
Do you have GSTIN	Yes	Mobile No.	8949549065
Email Id	ravneetsinghkalra@gmail.com	Social Category	General
Gender	Male	Specially Abled(DIVYANG)	No
Date of Incorporation	24/01/2005	Date of Commencement of Production/Business	24/01/2005

Bank Details

Bank Name	IFS Code	Bank Account Number
AXIS BANK LTD	UTIB0000067	921020022473408

Employment Details

Male	Female	Other	Total
30	10	0	48 48 Anorised Supering

Investment in Plant and Machinery OR Equipment (in Rs.)

S.No.	Financial Year	Enterprise Type	Written Down Value (WDV)	Exclusion of cost of Pollution Control, Research & Development and Industrial Safety Devices	Net Investment in Plant and Machinery OR Equipment[(A)-(B)]	Total Turnover (A)	Export Turnover (B)	Net Turnover [(A)-(B)]	Is ITR Filled?	ITR Type
1	2021-22	Small	6286240.00	0.00	6286240.00	105549856.00	0.00	105549856.00	Yes	ITR - 3, 5, 6
2	2020-21	Micro	6838815.00	0.00	6838815.00	25057674.00	0.00	25057674.00	Yes	ITR - 3, 5, 6
3	2019-20	Micro	8700796.00	0.00	8700796.00	40063587.00	0.00	40063587.00	Yes	ITR - 3, 5, 6
4	2018-19	Small	10236346.00	50000.00	10186346.00	45583201.00	0.00	45583201.00	Yes	ITR - 3, 5, 6

Unit(s) Details

SN	Unit Name	Flat	Building	Village/Town	Block	Road	City	Pin	State	District
1	SYSTOLE REMEDIES PRIVATE LIMITED	VILLAGE OGLI	KALA AMB	DISTRICT SIRMAUR		TEHSIL NAHAN	KALA AMB	173030	HIMACHAL PRADESH	SIRMAUR
2	SYSTOLE REMEDIES PRIVATE LIMITED	E-100KH- 24/19	WEST KARAWAL NAGAR	KARAWAL NAGAR		20 FT. ROAD	DELHI	110094	DELHI	NORTH WEST

Official address of Enterprise

Flat/Door/Block No.	TRILOKPUR ROAD	Name of Premises/ Bu	ilding	12 / N	SYSTOLE REMEDIES PVT LTD
Village/Town	OGLI	Block 🗼	Proly	V	OPPOSITE PETROL PUMP
Road/Street/Lane	TRILOKPUR ROAD	City	Exp. 4	:11-00-1/4	KALA AMB
State	HIMACHAL PRADESH	District	3	16	SIRMAUR, Pin: 173030
Mobile	8949549065	Email:	VT.	Orin	ravneetsinghkalra@gmail.com
Latitude	30.666801776939256 Attests	Longitude:		(a. b.)	77.46754481396883

National Industry Classification Code(S)

5	SNo.	Nic 2 Digit	Nic 4 Digit	Nic 5 Digit (Harrana)	Activity
		21 - Manufacture of pharmaceuticals, medicinal	2100 - Manufacture of pharmaceuticals, medicinal	21001 - Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives;	Manufacturing

				60
	chemical and botanical products	chemical and botanical products	sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.	39
2	21 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	21002 - Manufacture of allopathic pharmaceutical preparations	Manufacturing
3	21 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	21003 - Manufacture of `ayurvedic' or `unani' pharmaceutical preparation	Manufacturing
4	21 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products	21005 - Manufacture of veterinary preparations	Manufacturing
5	20 - Manufacture of chemicals and chemical products	2023 - Manufacture of soap and detergents, cleaning and polishing preparations, perfumes and toilet preparations	20237 - Manufacture of cosmetics and toileteries (includes manufacture of pre- shave, shaving or after shave preparations; personal deodorants and anti- respirants; perfumed bath salts and other bath preparations; beauty or make-up preparations and preparations for the care of the skin, other than medicaments; manicure and pedicure preparations etc.)	Manufacturing

Are you interested to get registered on Government e-Market (GeM) Portal	Yes
Are you interested to get registered on TReDS Portals(one or more)	Yes
Are you interested to get registered on National Career Service(NCS) Portal	No
Are you interested to get registered on NSIC B2B Portal	No
Are you interested in availing Free .IN Domain and a business email ID	No
District Industries Centre	
MSME-DFO	KALAAMB (HIMACHAL PRADESH)
Date of Udyam Registration	SOLAN (HIMACHAL PRADESH)
	13/03/2021
Date of Printing	20/02/2024

IEC Details	
IEC Number	AAJCS3700R
IEC Status	Active
IEC Registration Date	19092022
IEC Modifification Date	13022024

* Parely das (INDIA)
Responded Actions
Exp. U: 11-00-2000 C

Notary PARCHILLA (Maryana)

Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN: - 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

FORMAT- X

BANKDETAILSOFTHEBIDDER

01	Name of the Bank. Branch Name& address.	AXIS BANK OF INDIA
	Branch Code No.	SCO-10,SEC-10,PANCHKULA,H.R 000067
	Branch Manager Mobile No.	8054700671
	Branch Telephone no.	0172-4349501 Panchkula,branchhead@axisbank.com
	BranchE-mailID	
02	9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank.	160211002
03	IFSCcodeoftheBranch	UTIB0000067
04	TypeofAccount(Current/Savings).	CASH CREDIT
05	AccountNumber(asappearinchequebook)	923030004757899

(inlieuofthebankcertificatetobe obtained, please attachthe copy of original cancelled cheque issued by bank for verification of the above particulars).

I/We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information, I shall not hold M/s. Uttar Pradesh MedicalSuppliesCorporationLtd.(UPMSCL)responsible.lhavereadtheconditionsofthe

tender/agreemententeredandagreetodischargetheresponsibilityexpectedofme/fromthecompanyas a bidder /successful bidder.

edies p Date: CompanySeal Signature Place: (Nameofthepersonston) g&designation)

CERTIFIED THAT THE ARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Bank Seal with address

Signature of the authorized official of the bank.

Page56of71

www.systoleremedies.in

info@systoleremedies.in @

MANDATE	FORM
(ANNEXUR	

S.No.	Details Required		
	Company Name	SYSTOLE REMEDIES PVT LTD	
	PAN Number	AAJCS3700R	
	TIN Number		
	GST NO.	02AAJCS3700R2Z6	
	Date of Inception	28-11-2021	
	Legal status of the Bid	der Pyt Ltd Company	
	(Proprietorship/ Partners Pvt. Ltd. Company/ Limited Company)	hip/	
	License No. & Date	MNB/06/434 & MB/06/435 Date 13.11.2006	
	Issued By	Asst.Drug Controller cum Licensia	
	Valid Up to	Authority HQ Baddi H.P.	
	Postal Address of the Compa	NY VILLOGLIKALA AMB TEHEN	
	Telephone No.	NAHAN District.Sirmour H.P. 98285-06600	
	Fax No.	70203-00000	
	E-mail ID	diament of the second	
	Alternate E-mail ID	director@systoleremedies.in	
	NI	ravneetsinghkalra@gmail.com	
	Director / Director /	NO RAVNEET SINGH	
	Mobile No. / Phone No	9828506600	Table 1 Table 1
	E-mail ID	ravneetsinghkalra@gmail.com	
	Name and Designation of the	Name:PINKI SHARMA	
	authorized company official	Designation:MANAGER	
	Mobile No.	7876892767	
***************************************	E-mail ID	Shpinki1988@gmail.com	
	Bank Details	1 - Cookeginan.com	
	a) Name of the Bank	AXIS BANK LTD	1+',0
	b) Branch Name & address	SCO-10,Sector-10,PANCHKULA HR	Rone details
- 4	e) Branch Code No.	UTIB0000067	-13
(Branch Manager Mobile No.	80547-00671	Vertor and
e) Branch Telephone no	+91-172-4349501	V ence)
f) Branch E-mail ID	Panchkula bar 11	bank becords
	9-digit MICR code number of	Panchkula, branchhead@axisbank.com	
tl	he bank and branch appearing on	160211002	20
tl	ne MICR cheque issued by the		
b	ank Branch		And Stage So
	Type of Account (Current /		1000 3000 1000
130	avings)	CC	SS No. cons SS No. cons DVP & Branch He
ch	Account Number (as appear in leque book)	923030004757899	DANGE

(In lieu of the bank certificate to be obtained, please upload the original cancelled cheque issued by your bank for verification of the above particulars).

Systole Remedies Pyl Ltd.

Remedies Pyl Ltd.

Director

DRUGSWING-TENDER FOR GENERAL MEDICINES

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold APMSIDC responsible. I have read the responsibility expected of me / from the company as a tenderer / successful tenderer.

Systole Remitde

Date: Place:

Company Seal...

..........Signature

(Name of the person signing & designation)

Ravneet Singh) (Director)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Remedies Paris Signature Andrews Remedies Paris Rem

Bond



Indian-Non Judicial Stamp Haryana Government



Date: 26/02/2025

₹0

Certificate No.

P0Z2025B50

(Rs. Only)

GRN No.

128675729

Penalty:
(Rs. Zero Only)

Stamp Duty Paid: ₹ 101

<u>Deponent</u>

Name:

Systole Remedies Pvtltd

H.No/Floor: Na City/Village: Ogli

NI

Sector/Ward: Na

District : Sirmaur

Landmark: Kalaamb

State: Himachalpradesh

Phone:

70*****56

Purpose: FOR TENDER PURPOSE OF SYSTOLE REMEDIES PVT LTD to be submitted at Na

The authenticity of this document can be verified by scanning this QrCode Through smart phone or on the website https://egrashry.nic.in



FORMAT - XI

LetterofAuthorization

POWEROF ATTORNEYFORSIGNINGOFBID

Know all men by these presents, We, SYSTOLE REMEDIES PVT. LTD. VILLAGE OGLI, KALA AMB, TEHSIL NAHAN DISTT SIRMOUR-173030 do here by irrevocably constitute, nominate, appoint and authorize Mr.RAVNEET SINGH (Director) OF SYSTOLE REMEDIES PVT. LTD. S/O Sri JITENDER SINGH and presently residing at VILLAGE OGLI, KALA AMB, TEHSIL NAHAN DISTT SIRMOUR-173030, who is presently employed with us/ the Lead Member of our Consortium and holding the position of DIRECTOR as our true and lawful attorney (here in after referred to as the "Attorney") to do in our name and on our behalf, all such acts, deeds and things as are necessary or required in connection with or incidental hereto submission of our bid for procurement of Drugs in Uttar Pradesh Medical Supplies CorporationLimited (the "Authority") including but not limited to signing and submission of all applications, bids and other documents and writings, participate in bidders' meetings and other conferences and providing information/responses to the Authority, representing us in all matters before the Authority, signing and execution of all contracts including butnot limited to the Agreements and undertakings consequent to acceptance of our bid, and generally dealing with the Authority in all matters in connection with or relating to or arising out of our bid for the procurement of drugs.

Weherebyratifyandconfirmallacts, deeds and things lawfully done or caused to be done by our said Attorney pursuant to and in exercise eof the powers conferred by this Power of Attorney and that all acts, deeds and things done by our said Attorney in exercise of the power shere by conferred shall always be deemed to have been done by us.

INWITNESSWHEREOFWE, SYSTOLE REMEDIES PVT. LTD. THE ABOVE NAMED PRINCIPAL HAVE



EXECUTED THIS POWER OF ATTORNEY ON THIS DAY OF 27.01.2025

For SYSTOLE REMEDIES PVT. LTD.

(Director)

Witnesses:

1.PINKI SHARMA

#208, SAINI VIHAR

PHASE 5, BALTANA-

ZIRAKPUR

2.

PRINCE KUMAR

#124, KISHANGADH

Accepted

RAVNEET SINGH

(Authorized Signatory)



Identify the deponent Executant
Who has Signed/Thumb Marked In my Presence

205713/698/242.

Attested as Identified

Notary Panchkula

- 1 APR 2025







Memorandum
And
Articles
Of
Association
Of

Systole Remedies Private Limited

Systole Remedies Pvt. Ltd.

Semedies Pvy.

Semedies

Thorised Supplies

Attested to De Tura Demis

29 MAR 2025

Notary, (ANCHKULA (Haryana)



FORM NO. I.R निगमन का प्रमाण-CERTIFICATE OF INCORPORATION

सी आई एनं... यु24230 रचपी 2005पी दी सी 27885 CIN.... U24230HP2005PTC27889

में एतद् द्वारा प्रमाणित करता हूं कि आज. सिंह दोल रेमेडी ग्रं प्राइवेल लिमिनेड

प्वनी अधिनियम 1956 (1956 का 1) के अधीन निगमित की गई है और यह कम्पनी परीसिमित

thereby certify that SYSTOLE REMEDIES PRIVATE LIMITED

this day incorporated under the Companies Act, 1956 (No.1 of 1956) and the company is limited.

मेरे हरताक्षर से आज ता०..... 24-01-2005

Given under my hand at JALANDHAR this....24th

day of January Two Thousand Five.

(4th Magha, 1926 Saka)

कम्पनियों का रिजस्ट्रार

पंजाब हि॰ प्र॰ एवं चण्डीगढ़ Registrar of Companies

Punjab, H.P. & Chandigarh

NOWLY, PANCHICULA (

FORM NO. DIR-12
[Pursuant to sections 7(1) (c). 168 & 170 (2) of The
Companies Act, 2013 and rule 17 of the Companies
(Incorporation) Rules 2014 and 8, 15 & 18 of the
Companies (App. 2014) and Qualification of
Directors) Rules 2014 and Qualification of



Particulars of appointment of directors the key managerial personnel and changes among them and the

Form Language • Engli Refer the Instruction kit for fi 1. This form is for Nev	sh O Hindi	यमव ज्ञापने Company	
2. (a) * Corporate Identity No	umber (CIN) of company	U24230DL2005PTC191854	
(b)Global location number (GLN) of company		Pre-fill
3. (a) Name of the company	SYSTOLE REMEDIES P	RIVATE LIMITED	
(b) Address of the registered office of the company	E-100 KH-24/19, 20 FT. I WEST KARAWAL NAGA DELHI Delhi 110094 India	ROAD	•
(c) E-mail ID of the company	srpi777@yahoo.com		
Number of Managing director		e form is being filed	
. Details of the Managing C	Director, directors of the	company	2

Systole Remodil s Pvt. Ltd.

Director

Attested to Be True Copy Page 1 of 6 Notary, PANCHIGULA (Maryana)

Systole Remedies Pvt Ltd

Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

BOARD RESOLUTION

Extracts of the Minutes of the meeting of Board of directors of the company, at its registered office at Systole Remedies Pvt Ltd,Vill. Ogli, Kala Amb, Distt. Sirmour H.P. duly convened and Full Quorum was present on 01/04/2023.

RESOLVED THAT the board decided to enroll the company of Procurement of Tender for the Annual Rate Contract for Supply of Pharmaceuticals to Various destination of Government Institution for the board has authorized * to MR. RANVEET SINGH , Address: #-267, Sector-26, Panchkula Haryana-134116 as Authorized Signatory and who is the DIRECTOR of the company to do all the necessary formalities and compliances of tender.

Specimen Signature of Authorized Signatory For Systole Remedies Pyt. Ltd.

Signature(Ravneet singh)

For and on behalf of Board of Directors of M/s. SYSTOLE REMEDIES Pvt. Ltd.

(Jitender Mohan Kalra) Director (Director)

Attested to Be Tra

Notary, PANCHKULA (Haryana)

gemedies

info@systoleremedies.in @

www.systoleremedies.in



O Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

10	60 days' production capacity (Dosage form wise) for all premises certified by Licensing Authority (This requirement is not for importers quoting for imported drugs).	Yes	27-27	
11	Averageannualturnoverstatement(Format–VI)alongwith audited balance sheet.	Yes	28-28	
12	Acceptanceofallterms&conditionsinallSectionsofTender document. (Declaration as per Format –VII)	Yes	29-30	
13	Manufacturing/Importexperience(AsperFormat-VIII)	Yes	31-32	
14	ListofGovt.organizationtowhichbidderisanexistingsupplier (As per Format – IX)	Yes	33-33	
15	GSTregistrationcertificate.	Yes	34-36	
16	AffidavitofbeingaSSI/MSMEunitofUttarPradesh(If applicable)	Yes	37-39	
17	Copyoffirm'sPANcard.	Yes	40-40	
18	BankDetailsof thebidder.(Asper Format–X)	Yes	41-43	
19	LetterofAuthorization(AsperFormat – XI)	Yes	44-45	
20	Otherdocumentsforestablishingeligibilityofbidder	Yes	46-52	
21	Otherdocumentif askedbyTIA	Yes	53-116	
22	ChecklistasperFormat-XIII	Yes	117-118	
23	CommittedQuantityforUPMSCL(AsperFormat–XVII)	Yes	119-119	

Note: BOQ/Price bid has to be uploaded in the specific template in tender portal and shall not be included as part of the technical bid. Integrity pact & Agreement are not required to be submitted as part of the bid as the same would be required to be furnished by qualified bidders to whom contracts shall be awarded.

Attested as legatified

Notary, PANZHKULA (Haryana)

2 9 MAR 2025 Page**60**of**67**



🕠 Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

FORMAT-XIII CHECKLIST



The bidders are hereby instructed to upload the following documents as per the checklist and must mention the page numbers against each column of the checklist. The documents should be page numbered & arranged serially, self-attested, stamped by the authorized signatory and attested by public notary.

Checklistsheetismandatoryto fill&thedocumentsoftechnicalbidshouldbearranged in accordance to checklist

S.	Descriptionofthe document	Yes/No	Page	Rem
No.			no.	arks
1	Descriptionofthebidder:Shouldincludetheinformationasked in Format – I	Yes	1-1	
2	Copyofe-TransferReceiptfordepositoftenderprocessingfee along with Format – II	Yes	2-2	
3	Copyofe-TransferReceiptfordepositofEMDalongwith Format-III/Copyofexemptioncertificate.	Yes	3-3	
4	List ofmanufacturingpremisesat whichquoteddrugsaretobe manufactured (Format – IV)	Yes	4-4	
5	Copy of Valid GMP and GLP/WHO-GMP certificate of manufacturing premises is sued by Licensing Authority.	Yes	5-6	
6	Non-Convictioncertificateissuedbylicensingauthorityfornon conviction (Either currently valid or issued within 6 months prior to publication of the tender) for all premises.	Yes	7-7	
7	List of itemsforwhichbidisquoted(AsperFormat–V)	Yes	8-9	
8	Copy of the Manufacturing/import licenses with validity & drugs approval proof of all items quoted. (The items quoted should be highlighted & drug code shall be indicated).	Yes	10-22	Remedies
9	Market Standing Certificate/ Manufacturing and Marketing CertificateforthedrugsquotedissuedbyLicensingAuthority	Yes	23-26	2

29 MAR 2025 Page**59**of**67**

Notary/PANCHKULA (Haryana



Village Ogli, Kala Amb, Tehsil Nahan, Distt Sirmaur, HP-173030

GSTIN:- 02AAJCS3700R2Z6

Mfg. Lic. No. MB/06/435; MNB/06/434

FORMAT-XVII

Committed Quantity for UPMSCL

S. No.	ItemCod		Monthly Capacityin allshiftsin nos.	Ann ual Prod uctio n Capa city	Monthly supply Commitm ent to UPMSCL innos.	contract period (31- October-	Estimated BidQuantity as per Annexure-A Schedule of requirement
1	D100046	Atorvastatinealcium tabletIP40mg1*10strips	1.5CR TAB	18CR.	1.5CR TAB	1,00,00,000	1,00,00,000
2	D040089	CefuroximeaxetilTabl etIP500mg 1*4strips	1.5CR TAB	18CR.	1.5CR TAB	25,00,000	25,00,000
3	D260003	Febuxostat40mgtab1*	1.5CR TAB	18CR.	1.5CR TAB	10,00,000	10,00,000
4	D280050	Levecetram100mg/mlInjection5mlVial	7.8LAC	93.60LAC	7.8LAC	50,000	50,000
5	D280057	-	1.5CR TAB	18CR.	1.5CR TAB	10,00,000	10,00,000
6		Meropenem250mginjd rypowderwithwaterco mbi pack 1*1dry powderVial		93.60LAC	7.8LAC	1,00,000	1,00,000
_		MethylprednisoloneInj7 ection40mg/ml(1ml)1 mlvial	'.8LAC	93.60LAC	7.8LAC	1,00,000	1,00,000
		Pantaprazole40mg(tab)1*10strip	5CR TAB	60CR.	5CR TAB	5,00,00,000	5,00,00,000
9	D340033	Thiamineinjection 100 7 mg/ml,2mlVial	.8LAC	93.60LAC	7.8LAC	50,000	50,000

Attested as ligntified

Notary PANGHKULA (Hazyana)

NOTAR PARAMENTAL PARAM

Remedies Pur.

29 MAR 2025

Page67of67



UTTAR PRADESH MEDICAL SUPPLIES CORPORATION LTD.

(A Government of Uttar Pradesh Undertaking)

Regd. Office: SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension, Lucknow-226 002

Corrigendum-5 dated 27/01/2025

With reference to tender no. UPMSCL/Drugs-223/25 dated 14 November, 2024, a corrigendum is being issued as follows:

Technical Corrigendum: A. List of items withdrawn from tender

S No	Drug Code	Description	Estimated annual quantity	Minimum Shelf life required (in
1	D220007	Acetic acid solution 5%, 100ml bottle	20,000	months)
2	D040096	Acyclovir oral liquid 200 mg/5 ml 100 ml	100,000	24
3	D020009	Antacid containing magnisium hydroxide 250 mg, aluminium hydroxide 250mg and simethicone 50mg syrup 1*170 ml bottle	2,500,000	24
4	D110014	Artesunate powder for injection 120 mg with diluent	50,000	24
5	D040093	Cefazolin Powder for injection 1000 mg with water for injection 10 ml 1*1 dry powder liquid	500,000	24
6	D040092	Cefazolin Powder for injection 500 mg with water for injection 10 ml dry powder liquid 1*1 dry powder liquid	500,000	24
7	D340028	Cholecalciferol oral dosage 60000 IU, soft gelatin 1*10strip	2,500,000	36
8	D340035	Cholecalciferol oral drops 400 IU/ml 15 ml with	100,000	24
9	D080030	Donepezil 5mg 1*10strip	200	
10	D040090	Doxycycline oral suspension 50 mg/5 ml (60ml) 1*60ml dry powder	200,000	36 24
11	D230023	Ferrous salts (a) Iron Dextran (b) Injection 50 mg/ml, 2ml Ampoule/Vial	20,000	24
12	D130030	Formetrol 6mcg+Budesonide 400mcg nebulising solution 1* Traspule to 5e 1	500,000 13 Copy * P#	GH 24 10000 1000 1000 1000 1000 1000 1000
13	D290020	Glycerin/glycerol topical Marid 100 ml	50,000 Saryana 50,000	36
14	D050009	Hydroxy ethyl starch 6% Injection(6% Saline Solution for Infusion) 6% IV Infusion 500 ml FFS	10,000	36.
15	D280050	Levecetram 100mg/ml Injection 5ml Vial	70.00	1
16	D280057	Leveracetam tab 500 mg 1*10strips	50,000	36 Chorised Sign
7	D180022	Levonorgestrel tab 1.5mg 1*10strip	1,000,000	N 48

,	/	1
1	10	
-		-

S No	Drug Code	Item Description	Estimated annual quantity	Minimum Shelf life required (in
18	D310003	Levothyroxine 25mcg tablet 1*100 bottle	500,000	months)
19	D310004	Levothyroxine 50mcg (0.5mg) tablet 1*100 bottle	1,000,000	24 24
20	D220008	Lugol's iodine solution 5% 50 ml bottle	20,000	
21	D180012	Medroxyprogestrone acetate 10mg tablet 1*10strip	500,000	24 36
22	D040094	Meropenem 250 mg inj dry powder with water combi pack 1*1dry powder Vial	100,000	24
23	D070014	Metoclopramide syrup 5 mg/5 ml (p) 1*5 ml phial	1,000,000	24
24	D340034	Multivitamin Tablet:- Vitamin A 400mcg, Thiamine 0.7mg, Riboflavin 0.8mg, Vitamin B6 0.8mg, Vitamin B12 1mcg, Folic Acid 75mcg, Nilacin 9mg, Pantothenic Acid 3mg, Vitamin C 40mg, Vitamin D 10mg tablet 50 bottle	20,000,000	24
26		Olanzapine: 10mg/ml Injection 10mg/vial	10,000	24
27	D110011	Quinine tablet 300 mg 1*10strip	100,000	36
28	D170005	Senna tab Pack of 100 Bottle	500,000	36
	D280054	Sertaline hydrochloride 50 mg 1*10strip	4,000,000	36
29	D350003	Tamsulosin HCL capsules 400mcg 1*10strip	3,000,000	24
30	D040091	Terbinafine Tab 250mg 1*10strip	1,000,000	26
31	D340032	Thiamine tablet 100 mg 1*10strips	5,000,000	36
32	D010038	Trypsin Chymotrypsin tab (100000AU) 1*10strip	3,000,000	36 24

Technical Corrigendum: B. List of items with updated drug codes

Sr. No.	Item Description	Item Code	Revised item code
1.	Fentanyl citrate injection 50 mcg/ml (2ml) 2 ml vial	D010011	D010044
2.	Olanzapine: 10mg/ml Injection 10mg/vial	D280028	D280059
3.	Tenecteplase 30 mg/vial with 10ml water for inj 1*1dry powder Vial	D050006	D050010

All other terms & conditions of the tender document shall remain same.

MANAGING DIRECTOR UPMSCL

Attested to B

NAIB SINGH Notary, PANCH (ULA (Haryana)

Page 2 of 2





UTTAR PRADESH MEDICAL SUPPLIES CORPORATION LTD.

(A Government of Uttar Pradesh Undertaking)

Regd. Office: SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension, Lucknow-226 002

Corrigendum-6 dated 28/01/2025

With reference to tender no. UPMSCL/Drugs-223/25 dated 14 November, 2024, a corrigendum is being issued as follows:

Reference of Tender Document	Existing Date	Revised Date
Last Date and Time for Online Submission of Tender	28 th January, 2025 UPTO 15:00 Hrs.	30 th January, 2025 UPTO 15:00 Hrs
Date and Time of Opening of Technical BID-COVER 'A'	28 th January, 2025,15:30 Hrs	30 th January, 2025,15:30 Hrs

Note: Tender has been extended due to technical issue in e tender portal.

All other terms & conditions of the tender document shall remain same.

MANAGING DIRECTOR UPMSCL

Remedi

Attested to Be True Copy

Notary, FANCHKULA (Haryana)

29 MAR 2025

Page 1 of 1